



MONASH
University

MONASH
MEDICINE
NURSING AND
HEALTH SCIENCES

MONASH
ADDICTION
RESEARCH
CENTRE

2023-2024
ANNUAL REPORT

2023-2024 SNAPSHOT



146 MEMBERS

MARC's membership has grown to 146 academics from across Monash, making it one of the largest addiction research centres in the world.



208 PUBLICATIONS

Our members published 208 peer-reviewed journal articles in the field of addiction, with 76% published in Q1 journals.



OVER \$18M IN FUNDING

Our members received over \$18M in funding to complete addiction-related research.



288 MEDIA MENTIONS

MARC researchers appeared in the media more than 280 times, including across radio, TV, online & print media.

CONTENTS

About Us	3
Message From The Directors	4
Governance	5
MARC Theme Leaders	6
MARC Advisory Board	7
Inaugural MARC Emerging Researcher Symposium	8
Funding Success	9
Completed Research	12
Policy And Engagement	14
Thought Leadership	16
Media	19
Our Collaborators	23
Publications	24

ABOUT US

The Monash Addiction Research Centre (MARC) brings together world-leading expertise from across Monash University and the sector to provide solutions to the challenges of addiction.

We have 146 academic members across 30 departments in six faculties and two institutes, making us one of the largest addiction research centres in the world.

Our mission is to provide national thought leadership, education and research excellence to develop, deliver and evaluate effective policy and practice approaches for addiction. We work in partnership to achieve this by:

USING DATA FOR IMPACT

We generate and leverage multiple unique datasets, and provide timely and accessible insights to drive policy and practice change.

TRANSFORMING PRACTICE

We work to transform practice through co-designing, trialling and implementing novel evidence-based approaches. We work with community partners in the Frankston-Mornington Peninsula, those with lived experience of addiction, and other key stakeholders to develop local solutions that can be scaled nationally.

CHANGING THE CONVERSATION

We directly address stigma and community perceptions of addiction by bringing together multiple perspectives, including lived experience, through thought leadership, expert commentary and evidence dissemination.

ENABLING THE WORKFORCE

We build the expertise of individuals working in addiction and other frontline workforces, and the capacity of the treatment sector more broadly. We achieve this through the development and delivery of short courses, embedded addiction curricula and work-integrated learning opportunities. We work with government partners to deliver effective reforms in addiction and mental health care.

OUR AIM

MARC is dedicated to finding solutions that transform the way we think about and respond to addiction.



MESSAGE FROM THE DIRECTORS

We are pleased to present the Monash Addiction Research Centre's Annual Report for 2023-2024

Each year, the Centre builds upon its work and influence, and the 23/24 financial year was no exception. In the last financial year, MARC members across Monash University secured over \$18M for addiction-related research and published over 200 peer-reviewed addiction-related articles. This is an extraordinary achievement, and we congratulate all our members on an outstanding year. This success demonstrates the enormous impact MARC members are making in the field of addiction and the importance of interdisciplinary collaboration in finding solutions to the challenges of addiction.

Throughout the year, MARC held several impactful events, including the well-attended inaugural MARC Emerging Researcher Symposium, bringing together early to mid-career researchers and PhD students engaged in addiction-related research from across Monash University. Highlights included an inspiring keynote on the career paths of clinician-researchers and a panel discussion on academic publishing.

The number of talented PhD students within MARC continued to grow, and the MARC PhD network expanded to 31 members. Our commitment to professional development also continued. In August 2023, MARC hosted a webinar on research impact and in October 2023, PhD network members had the opportunity to tour and learn about the Medically Supervised Injecting Room in Richmond.

In the 23/24 financial year, MARC researchers were very active in the policy and advocacy space, with engagement in state and federal government inquiries, including the Victorian consultation on landmark reforms to reduce gambling-related harm and money laundering and the Victorian Department of Justice and Community Safety's consultation on gaming machine monitoring arrangements.

Many MARC members were recognised for their outstanding achievements. Highlights include a 2023 Victorian Tall Poppy Science Award awarded to A/Prof Shalini Arunogiri and prestigious NHMRC Investigator Grants awarded to A/Prof Joe Doyle, MARC Deputy Director Prof Suzanne Nielsen and Dr Aili Langford.

MARC researchers also attracted wide media attention, with over 280 appearances across various platforms, including radio, TV, online and print media.

These accomplishments, driven by the dedication of our members and core staff, reflect the collaborative spirit of the MARC community. Reflecting on the achievements of the past financial year, we are thrilled with the momentum that we continue to build as a research centre.

On behalf of MARC, we extend our sincere thanks to our advisory board, theme leaders, members, research partners and the community for their unwavering support. We look forward to another successful year in 2025.

PROFESSOR DAN LUBMAN AM
Director

PROFESSOR SUZANNE NIELSEN
Deputy Director

GOVERNANCE

Centre Director, Prof Dan Lubman AM, oversees the Centre's research and operations and plays a key role in the advancement of industry engagement activities.

Deputy Director, Prof Suzanne Nielsen, plays an instrumental role in fostering research collaborations and in the strategic development of key initiatives in the Frankston-Mornington Peninsula region. Other core staff include members of the strategy and business operations team.

EXECUTIVE MANAGEMENT / SENIOR LEADERSHIP



PROFESSOR DAN LUBMAN AM
Director



PROFESSOR SUZANNE NIELSEN
Deputy Director

STRATEGY AND BUSINESS OPERATIONS



KRISTA CRAWFORD
Research Program Officer



JONATHAN MEDDINGS
Policy and Engagement Manager

RESEARCH STAFF



DR TINA LAM
Senior Research Fellow



DR BOSCO ROWLAND
Statistician and Senior Research Fellow



DR LOUISA PICCO
Research Fellow



DR TING XIA
Research Fellow



DR ALI CHEETHAM
Research Fellow



KRISTY MCGREGOR
Research Officer



ROSE LAING
Research Officer

MARC THEME LEADERS

MARC's theme leader group is collectively responsible for informing the strategic direction of MARC and sharing information relating to activities and opportunities within MARC. Theme leaders represent one of three key research themes within MARC, acting as a conduit for information between MARC and the departments and faculties in which they are based.

SCIENCE



PROF ANTONIO VERDEJO-GARCIA

Turner Institute for Brain and Mental Health



A/PROF JENNIFER SCHUMANN

Department of Forensic Medicine



DR AILI LANGFORD

Centre for Medicine Use Safety

PREVENTION AND TREATMENT



PROF PAUL DIETZE

Burnet Institute



PROF ARON SHLONSKY

Department of Social Work



PROF VICTORIA MANNING

Turning Point



A/PROF SHALINI ARUNOGIRI

Turning Point



DR TINA LAM

Monash Addiction Research Centre



A/PROF LIZ STURGISS

Department of General Practice

CULTURE AND POLICY



PROF PHILIP MENDES

Department of Social Work



PROF DENNIS PETRIE

Centre for Health Economics



A/PROF SONJA DE NEW

Centre for Health Economics



DR ROWAN OGEIL

Turning Point



DR MICHAEL SAVIC

Turning Point

MARC ADVISORY BOARD

MARC's external Advisory Board is comprised of representatives from a broad range of key stakeholders and partners, bringing together a wealth of expertise and leadership. The board assists MARC in its mission to provide national solutions to the problems posed by addiction by increasing the visibility of the Centre within the community and supporting the work of our members.

CHAIR



Mietta Gibson has a commerce degree and has had a successful career in Human Resources, working for companies such as Daimler, Fiat Chrysler, World Vision and MYOB. In recent years, Mietta has been working as a consultant alongside leaders and teams at a variety of organisations to create positive and inspiring workplaces.

Ms Gibson has also been involved with the Gibson Family foundation, a small foundation interested in creating impact in areas such as mental health.

Being chair of the MARC Advisory Board offers Mietta a great opportunity to combine her professional experience with her lived experience of having a family member with addiction and mental health issues, and to represent her Mornington Peninsula community.

BOARD MEMBERS

SIMONE CORIN

Executive Director, Children and Families Division, Victorian Department of Health and Human Services

NICOLA REINDERS

Executive Director: Quality and Patient Experience, Ambulance Victoria

DR ALISON DWYER

Executive Director, Research (Chief Medical Officer), Eastern Health

SAM BIONDO

Executive Officer, Victorian Alcohol and Drugs Association

AC GLENN WEIR

Assistant Commissioner, Road Policing Command, Victoria Police

PROF KIM CORNISH (SIR JOHN MONASH DISTINGUISHED PROFESSOR)

Director, Turner Institute for Brain and Mental Health

CHRISTOPHER CARTER

CEO, North Western Melbourne Primary Health Network (NWMPHN)

DR ZIAD NEHME

Director of Research and Evaluation, Ambulance Victoria

CLARE DAVIES

CEO, Self Help Addiction Resource Centre

PROF DAVID COPOLOV AO

Pro Vice-Chancellor (Major Campuses and Student Engagement), Monash University

ROD MACKINTOSH

South East Public Health Unit. Health Promotion and Partnerships. Monash Health

NICOLE LYNCH

Executive Director, Strategy & Policy, Mental Health and Wellbeing Division, Department of Health

ELEANOR WILLIAMS

Executive Director, Strategy & Policy, Mental Health and Wellbeing Division, Department of Health

INAUGURAL MARC EMERGING RESEARCHER SYMPOSIUM

In May, MARC held its inaugural emerging researcher symposium, showcasing the work of early and mid-career researchers and PhD students engaged in addiction-related research across Monash University. MARC member A/Prof Shalini Arunogiri (Clinical Director of the Hamilton Centre, Victoria's Statewide Centre for Mental Health and Addiction) delivered an inspiring keynote address for the attendees on the career paths of clinician-researchers. Additional valuable advice on academic publishing was shared during a panel discussion with MARC members Prof Paul Dietze (co-Director of the Disease Elimination Program, Burnet Institute, and Head of the Melbourne office of the National Drug Research Institute), Prof Suzanne Nielsen (Deputy Director, MARC), Dr Tina Lam (Senior Research Fellow, MARC), and panel moderator Dr Louisa Picco (MARC, NHMRC Emerging Leader Research Fellow).



The winner of the best PhD presentation was Richard Armour, for his presentation titled "Performance of the Medical Priority Dispatch System in identifying patients requiring chest compressions at overdose prevention services: A retrospective cohort study".



The winner of the best early and middle-career researcher presentation was Dr Tejashree Kangutkar for her presentation titled "Perceived factors affecting the oral health care experience of people who use drugs and potential strategies for addressing these barriers".

FUNDING SUCCESS

MARC researchers were awarded more than \$18 million in research funding in the 23/24 financial year to conduct research on addiction, substance use and related behaviours. The below examples of funding success demonstrate the strength of interdisciplinary collaboration amongst our members.

USING WEB SCRAPING TO CONSTRUCT A WORLD-FIRST ALCOHOL RETAIL PRICING SYSTEM TO INFORM EVIDENCE-BASED ALCOHOL POLICIES

Investigators: Dr Tina Lam, Prof Dennis Petrie, Dr Brian Vandenberg, Sam Campbell, Prof Suzanne Nielsen

Funder: Monash Data Futures Institute

Alcohol is the leading risk factor for premature death and disability among people aged 15-49, and is one of the leading preventable causes of community harms such as family violence. Globally, government policies related to raising prices have been the most effective and least costly interventions to reduce alcohol-related harm, in both general and high-risk populations. However, policy makers do not have access to real-time price information for the development and evaluation of price policies.

This project will use web scraping technology to monitor daily fluctuations in prices across the Australian alcohol retail sector (~100M rows of price data per year). We will provide the most comprehensive price-based examinations of the retail alcohol market available across any for-profit economy, in order to inform the implementation of effective health policies to prevent alcohol harm.

CO-DESIGNING AN EVIDENCE-INFORMED, SCALABLE SCHOOL-BASED PROGRAM TO PROMOTE HELP-SEEKING FOR SUBSTANCE USE PROBLEMS

Investigators: Prof Dan Lubman, Prof Patrick Oliver, Adjunct Clinical A/Prof Christine Grove, Dr Alex Waddell, Dr Ali Cheetham, Dr Bosco Rowland, Dr Roisin McNaney, Dr Jue Xie, Jodie Matar

Funder: Medical Research Future Fund

This \$1.3 million grant will fund the next stages of development of the school-based health promotion program MAKINGtheLINK, which builds vital help-seeking skills and knowledge among young people faced with substance use or mental health problems. The aim of the project is to provide a scalable national solution to reducing alcohol and drug harm among adolescents by increasing the reach and uptake of the program.

This project is a collaboration between Monash University, RMIT University, University of Canberra, Headspace National Youth Mental Health Foundation, the Alcohol and Drug Foundation, Turning Point, Eastern Health, the Victorian Department of Education and the Australian Secondary Principals' Association.

VALIDATION OF RGAT, A PRODUCT HARM ASSESSMENT TOOL

Investigator: A/Prof Charles Livingstone

Funder: Victorian Responsible Gambling Foundation

This project will assess the validity of the RGAT, a gambling product harm assessment tool. The RGAT was prepared by the Victorian Responsible Gambling Foundation to support decision-making by the Victorian gambling regulator, the Victorian Gambling and Casino Control Commission (VGCCC). The VGCCC has begun to utilise this tool in assessing applications for new and revised or modified gambling products. However, the rigour of the tool will be enhanced by review of relevant research literature around harmful characteristics of gambling products, and the application of these research findings to the categories and characteristics of gambling products considered in the RGAT. Further, additional categories and characteristics of gambling products may be identified via the review of relevant literature, and these will be proposed for incorporation in the RGAT. Provision of an evidence base for the RGAT will provide better support for decision-makers, reduce the likelihood that harmful gambling products may be approved, and provide guidance to those seeking approval of gambling products.

EMPOWERING CONSUMERS WITH HEALTH LITERACY IN OPIOID SAFETY

Investigators: Prof Suzanne Nielsen, Prof Paul Dietze, Monika Boogs, Jarrod McMaugh, Dr Louisa Picco

Funder: Department of Health and Aged Care

This \$1.1 million grant was received to develop a Prescription Opioid Safety Toolkit. The co-designed Opioid Safety Toolkit will include information and evidence-based resources for consumers, carers and healthcare professionals. The Toolkit will be rigorously tested as part of a randomised controlled trial and will be disseminated nationally via community pharmacies and through our project partners, including consumer and health professional organisations.

This project is a collaboration between Monash Addiction Research Centre, the Burnet Institute, the Pharmaceutical Society of Australia and PainAustralia



NHMRC INVESTIGATOR GRANTS

Three MARC researchers were awarded more than \$5 million in prestigious NHMRC Investigator grants.

A/Prof Joe Doyle: Seventy million people live with hepatitis C globally. Hepatitis C causes early death and liver disease, with ongoing transmission chiefly among vulnerable groups. Eliminating hepatitis C as a public health threat by 2030 is a World Health Organisation global health priority. Through this grant, A/Prof Doyle's work will address key knowledge gaps in the elimination agenda. It will determine how effectively, efficiently and sustainably new models of care delivered to key populations accelerate progress toward hepatitis C elimination.

Prof Suzanne Nielsen: Preventable opioid overdose deaths and related harms are increasing. Yet, few people who experience such harms seek help. Treatment for opioid dependence is hard to access, and policy interventions may actually push people away from healthcare into non-prescribed and more hazardous use. Through this grant, Prof Nielsen's work will facilitate earlier help-seeking, increase the reach of overdose prevention, test novel ways to make treatment easier to access, and enable the identification of effective opioid policy.

Dr Aili Langford: Dr Langford's research aims to reduce medication-related harm caused by opioid analgesics (opioids). This will be achieved by supporting healthcare professionals and people living with chronic pain to safely and effectively reduce or stop opioids that may be causing more harm than benefit. Through this grant, Dr Langford will work with consumers, healthcare professionals and organisations to ensure findings are translated into practice to improve the quality of care for Australians taking opioids for chronic pain.

EXAMINING PHARMACOVIGILANCE AND HEALTH OUTCOMES WITH ACCESS TO UNAPPROVED PSYCHOACTIVE MEDICINES

Investigator: Myfanwy Graham

Funder: NHMRC PhD Scholarship

A growing number of medicines are available via special access pathways for prescription, including medicinal cannabis and psychedelics. Historically, these medicines were used for end-of-life care and other life-threatening conditions in the short term. Now, these medicines are commonly used for long-term mental health and pain conditions. This research project will produce new information on 1) patient safety, 2) patient access and use, and 3) healthcare professional educational needs.



COMPLETED RESEARCH

Below are some highlights of the impactful addiction-related research completed by our members in the 23/24 financial year.

DRUG HARM REDUCTION IN THE CITY OF MELBOURNE: IMPROVING ACCESS TO NALOXONE

Investigators: Dr Samantha Colledge-Frisby, **Dr Louisa Picco, Prof Suzanne Nielsen, Prof Paul Dietze**

Funder: The City of Melbourne

The Burnet Institute and the Monash Addiction Research Centre were commissioned to conduct the 'Drug Harm Reduction in the City of Melbourne' project. In response to rising opioid overdoses within the municipality, the Future Melbourne Committee (November 2023) committed to enhancing naloxone access. This resulting report provides an overview of overdose response strategies, key findings from a literature review, a summary of roundtable discussions, and five key recommendations for improving responses to opioid-related overdoses.

This project was a collaboration between the Monash Addiction Research Centre and the Burnet Institute.

Report

https://creidu.edu.au/system/resource/105/file/Burnet_Institute_and_Monash_University_report_-_City_of_Melbourne_Naloxone_Roundtable_final_April_2024.pdf

ENABLING EVIDENCE-INFORMED POLICY TO ADDRESS AUSTRALIA'S OPIOID CRISIS

Investigators: **Prof Suzanne Nielsen, Prof Simon Bell, Prof Grant Russell**, Samanta Lalic, Dr Paul Sanfilippo, Georgia Richards, **Prof Rachelle Buchbinder, A/Prof Nadine Andrew**, A/Prof Christopher Pearce, **Prof Dan Lubman**, Dr Elizabeth Deveny, **Dr Jenni Ilomaki, Dr Ting Xia, Monica Jung, Helena Cangadis-Douglass**

Funder: NHMRC Ideas Grant

Policies restricting opioid supply have recently been implemented to address rising opioid-related deaths in Australia, with little evidence of the impact of these policies. This study made significant advancements in our understanding of the impact of these opioid policy changes by leveraging the linkage of a unique primary care dataset with hospital data. We provided crucial evidence of a possible substitution effect following the recent implementation of Victoria's prescription drug monitoring program. This work informed a formal Regulatory Impact Statement submitted to the Department of Health, contributing to recent changes to the Victorian PDMP, such as the inclusion of pregabalin, gabapentin and tramadol in the PDMP from 3 July 2023 onwards.

We also found evidence of the impact of changing opioid policy on opioid-related emergency department (ED) visits and provided a detailed picture of opioid taper trajectories and how differing opioid tapering rates can be associated with increased or decreased harm.

Selected Publications

Xia T, Picco L, Buchbinder R, Haas R, & Nielsen S.

(2024). Association of state-level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia. *British Journal of Clinical Pharmacology*, 90(4), 1162-1172. DOI:10.1111/bcp.15996.

Nielsen S & Xia T. (2024). Interventions for reducing the prescribing of pharmaceutical opioids in Australia: Are they effectively reducing opioid harm? *The Medical Journal of Australia*, 220(6), 311-312. <https://doi.org/10.5694/mja2.52259>

Nielsen S, Picco L, Russell G, Pearce C, Andrew

N, Lubman D, Bell S, Buchbinder R & Xia T. (2023).

Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes. *International Journal of Drug Policy*, 117, 104053. DOI: 10.1016/j.drugpo.2023.104053



A RANDOMISED CONTROLLED TRIAL OF AAT-APP: A COGNITIVE “BRAIN-TRAINING” SMARTPHONE APP TO HELP REDUCE ALCOHOL USE IN PEOPLE ACCESSING ALCOHOL TREATMENT

Investigators: Prof Victoria Manning, Dr Joshua Garfield, Prof Yvonne Bonomo, Chantel Churchus, Shannon Bell, Kent Burgess, Peter Matthews, Dr David Jacka

Funder: Victorian Alcohol and Drug Association

This project tested whether “SWiPE”, a world-first personalised approach bias modification (ABM) app, improved treatment outcomes when delivered as an adjunctive intervention to people receiving counselling for alcohol problems. This was tested through a randomised controlled trial in which the outcomes of participants using SWiPE were compared to participants provided with a minimal version of the app which only measured their cognitive bias towards alcohol, but did not provide any training to modify it. The primary aim was to measure efficacy in terms of self-reported alcohol use.

At its conclusion, this project generated new empirical evidence on the effectiveness of this simple, low-cost, app-based cognitive training intervention for enhancing reductions in alcohol use when provided as an adjunctive treatment to clients attending outpatient treatment for alcohol use. ABM directly targets biases in the “bottom-up” processing of stimuli that are believed to trigger impulsive urges to drink alcohol. This likely complements the psychotherapeutic interventions that many counselling clients receive, which seek to strengthen “top-down” control over impulses and conscious decision-making, making it easier for clients to apply the tools and strategies learned in counselling. ABM may also strengthen the impacts of pharmacotherapies (e.g., naltrexone, acamprosate) that some outpatients receive on stimulus-driven triggering of alcohol craving. As well as reducing the triggering influence of alcohol-related stimuli, the uniquely personalised form of ABM that was developed for this app may strengthen motivations related to personally-relevant positive goals and healthy behaviours. Following further testing of app-based ABM, the investigators intend to seek funding to make this available for implementation in alcohol and other drug treatment services to translate the research and benefit Victorian alcohol treatment-seekers.

This project was a collaboration between Monash University, St Vincent’s Hospital Melbourne, Uniting ReGen, Start Health Group Limited and Odyssey House Victoria.

POLICY AND ENGAGEMENT

It was another active year in the policy space for MARC researchers.

In July 2023, the Victorian Government announced major reforms to reduce gambling harms. The reforms included a mandatory shutdown period from 4 am to 10 am, mandatory pre-commitment and carded play on all of Victoria's 27,000 poker machines, as well as load limits being reduced from \$1000 to \$100.

These reforms came after MARC and Turning Point researchers made a joint submission to the *Inquiry into the Victorian Auditor General's reports on regulating gambling and liquor and reducing the harm caused by gambling*. The submission outlined strategies to prevent and reduce alcohol and gambling-related harm, including the use of data on alcohol-related harms to inform liquor licensing and compliance processes; introducing a national, universal pre-commitment system for online gambling; and strengthening consumer protections related to both online and in-person gambling.

Also in July 2023, MARC members Dr Aili Langford, Prof Suzanne Nielsen and 15 other experts co-authored the first international guidelines for evidence-based deprescribing of opioid analgesics.

In August 2023, MARC Director Prof Dan Lubman AM, along with Turning Point's Manager of Telephone and Online Services Rick Loos, presented at the Victorian Public Accounts and Estimates Committee's *Inquiry into the Victorian Auditor-General's reports no. 99: Follow up of Regulating Gambling and Liquor (2019) and no. 213: Reducing the Harm Caused by Gambling (2021)*. During the public hearing, they discussed the importance of adopting a public health approach to gambling harms, as well as the need to break down stigma and service system silos to improve help-seeking and treatment retention and provide integrated treatment, care and support for people experiencing gambling harms.



In September 2023, MARC and Turning Point researchers made a joint submission to the *Victorian consultation on landmark reforms to reduce gambling-related harm and money laundering*. The submission made several recommendations to enhance consumer protections and reduce gambling-related harm.

In October 2023, MARC joined 76 other agencies from across Victoria in a statement calling on the Victorian Government to establish a drug-checking system and early warning service in Victoria. This statement drew on recommendations from the Coroners Court of Victoria and Drug Law Reform Committee, aiming to reduce the harms from Novel Psychoactive Substances.

In November 2023, MARC members Prof Suzanne Nielsen and Prof Paul Dietze attended a Melbourne City Council meeting where a motion was passed to convene a roundtable of stakeholders in the sector to discuss improving naloxone distribution. Prof Nielsen presented evidence supporting increased naloxone availability.

In December 2023, the Public Accounts and Estimates Committee released its report *Gambling and liquor regulation in Victoria: A follow up of three Auditor-General reports*, following a public inquiry. The report made 61 recommendations, 13 of which aligned with 9 recommendations MARC made in its submission to the parliamentary inquiry, including that “gambling treatment and support services transition from the Department of Justice and Community Safety to the Department of Health, given the high instances of co-occurring conditions for people experiencing gambling harm”.

In June 2024, MARC and Turning Point researchers made a joint submission to the *Victorian Department of Justice and Community Safety’s consultation on gaming machine monitoring arrangements*. The submission made several recommendations to ensure the monitoring system maximises opportunities for harm minimisation and prevents money laundering.

Through these policy and engagement activities, MARC researchers continue to advocate for people living with addiction, and their families, so that they are supported through evidence-based, health-led responses and their health and human rights are protected and promoted.

THOUGHT LEADERSHIP

GETTING AHEAD OF THE FENTANYL THREAT: WE NEED TO ACT NOW TO AVOID A PUBLIC HEALTH DISASTER – MONASH LENS

[Prof Suzanne Nielsen and Prof Dan Lubman](#)

Fentanyl is a highly-potent opioid prescription medication, primarily used as a patch applied to the skin to treat chronic cancer pain or acute pain caused by major trauma or surgery. It causes more fatal overdoses than heroin because it is up to 50 times more potent and has a faster onset of action, leaving little time for intervention.

In a *Monash Lens* piece, MARC members Prof Suzanne Nielsen and Prof Dan Lubman discussed the need for a coordinated national approach to overdose prevention, substance use and addiction.

[Read more](#)

THE LANDSCAPE OF OPIOID PRESCRIBING HAS CHANGED, BUT IS IT FOR THE BETTER? – MONASH LENS

[Dr Aili Langford and Prof Suzanne Nielsen](#)

Globally, opioid prescribing has increased significantly over the past three decades. In 2019, Australia had the eighth-highest level of opioid use in the world. Although opioids play an important role in managing pain, increases in prescription opioid use have led to more opioid-related deaths. In the 10 years from 2007-2016, opioid-related mortality doubled in Australia, with most deaths attributed to prescription opioids. Prescription opioids are used for medical treatment (e.g., for pain or opioid dependence treatment) and for nonmedical reasons (e.g., for their euphoric effects). Harms can occur with both medical and nonmedical use.

In a *Monash Lens* piece, MARC members Dr Aili Langford and Prof Suzanne Nielsen examined the current landscape of opioid prescribing and what Australia is doing differently.

[Read more](#)

OPIOIDS MORE POTENT THAN FENTANYL HAVE BEEN DETECTED IN AUSTRALIA. SO WHAT ARE NITAZENES? – THE CONVERSATION

[Prof Suzanne Nielsen, Dr Amanda Roxburgh and Richard Armour](#)

A new group of drugs called nitazenes have been detected in Australia. Concerns about the potential harms of these drugs, and that users do not know what they are taking, have resulted in government health alerts and drug-checking recommendations from the coroner.

In a piece for *The Conversation*, MARC researchers Prof Suzanne Nielsen, Dr Amanda Roxburgh and PhD student Richard Armour discussed the differences and similarities between heroin, fentanyl and nitazenes and proposed public health responses to mitigate the potential harm of these drugs.

[Read more](#)

CAN A DRUG LIKE OZEMPIC HELP TREAT ADDICTIONS TO ALCOHOL, OPIOIDS OR OTHER SUBSTANCES? – THE CONVERSATION

[A/Prof Shalini Arunogiri, Dr Leigh Walker and Dr Roberta Anversa](#)

Ozempic was initially developed as a treatment for diabetes. However, this drug is increasingly being prescribed for weight loss. Recently, there has been growing interest in another possible use for this drug: for the treatment of addiction.

In a piece for *The Conversation*, MARC researcher A/Prof Shalini Arunogiri and colleagues discussed the potential use of Ozempic for the treatment of addictions to alcohol, opioids and other substances.

[Read more](#)



IDENTIFYING OPIOID TAPERING PATHWAYS TO SAFELY STOP USE – MONASH LENS

[Monica Jung, Prof Suzanne Nielsen and Dr Ting Xia](#)

With an increasing number of Australians receiving prescription opioids to treat chronic pain over the last decade, opioid-related harms have been on the rise. Every day in Australia, almost 150 people are admitted to hospitals as a result of opioid harms, and three people each week die from drug-induced death involving opioids. Tapering has been recommended as a key strategy to reduce the harms caused by opioid use, improve pain management, and safely cease using opioids. The process involves gradually reducing the dose and frequency of the prescribed opioid until it can be safely ceased altogether.

In a *Monash Lens* piece, MARC researchers Monica Jung, Prof Suzanne Nielsen and Dr Ting Xia discussed the various factors associated with successful opioid tapering.

[Read more](#)

ZERO ALCOHOL DOESN'T MEAN ZERO RISK – HOW MARKETING AND BLURRED LINES CAN BE DRINKING TRIGGERS – THE CONVERSATION

[A/Prof Shalini Arunogiri and Anthony Hew](#)

The availability and sales of “zero-alcohol” products have soared in recent years. These products, which contain less than 0.5% alcohol by volume in Australia, have been designed to mimic the flavour, appearance and packaging of alcoholic drinks. The market for zero-alcohol products is predicted to continue growing at a faster rate than for alcoholic beverages.

In a piece for *The Conversation*, MARC researchers A/Prof Shalini Arunogiri and Anthony Hew discussed the potential risks of zero-alcohol products.

[Read more](#)



MEDIA

MARC continues to have a strong media presence across various media platforms, with regular expert public commentary provided to a wide range of mainstream media outlets including *ABC News*, *ABC Radio*, *SBS News*, *The Guardian* and *The Age*.

RADIO, PRINT AND ONLINE MEDIA - HIGHLIGHTS

Head Topics – 28 June 2024

Combination of varenicline and nicotine lozenges found to increase smoking abstinence

Monash News – 28 June 2024

Australian researchers present potential new treatment option for nicotine addiction

The Australian Financial Review – 26 June 2024

How the AFL got itself hooked on harmful gambling

Hospital and Healthcare – 25 June 2024

Vic's implementation trial for pill testing welcomed

Pedestrian - 25 June 2024

Victoria will finally trial pill testing this summer: Everything we know so far

newsGP – 24 June 2024

Opioid tool aims to help GPs have 'challenging' conversations

newsGP – 20 June 2024

Only 29% of clinical guidelines offer advice on deprescribing

Nexus News Feed – 19 June 2024

A 'raft of unanswered questions' remain as Australia's first psychedelic therapy clinic opens

Monash Lens – 13 June 2024

Tackling negative healthcare bias in addiction treatment

Physicians Weekly – 27 May 2024

Co-design of digital public health substance use resources: A collaboration between young people and experts.

The Canberra Times – 27 May 2024

Simply reducing the number of pokies won't curb damage. Here's why

CBD News – 22 May 2024

Fight to save lives continues as community reacts with mixed emotions to injection room scrap

The Briefing – 20 May 2024

Nitazene - the super-strength opioid turning up in our party drugs

The Age – 13 May 2024

Pokies will close six hours a day, but gambling losses are expected to increase

The Guardian – 10 May 2024

'Alarming' rise in drug overdoses in Australia as heroin-linked deaths surge 40%

The Guardian – 2 May 2024

Researchers urge more Australian pharmacies to stock anti-opioid overdose drug naloxone

Monash News – 2 May 2024

New data shows naloxone availability is improving but there is no time to lose for action on overdose prevention

The Herald Sun – 1 May 2024

More music festival drug overdoses in Victoria than in 2023

3CR – 30 April 2024

Victorian government's rejection of a second safe injecting room in Melbourne CBD and its impacts on the community

Mornington News – 30 April 2024

Dozens dead from drugs in Frankston

ABC News – 30 April 2024

Victorian government scraps plans for a second supervised injecting room in Melbourne

North West Telegraph – 28 April 2024

Leading gambling expert warns Crown Sydney doesn't deserve 'second chance' after green light given to \$2.2bn casino

The Herald Sun – 26 April 2024

ODs Kill twice as many as road toll

The Australian – 26 April 2024

Naloxone access needs to improve as opioid crisis deepens across Australia

Medical Republic – 23 April 2024

Vic cans new injecting room as synthetic opioids hit streets

The Australian – 23 April 2024

Deadly drug sparks testing centre push

The Guardian – 23 April 2024

'Will cost lives': Addiction experts condemn decision to scrap proposed safe injecting room in Melbourne's CBD

The Guardian – 23 April 2024

Academics express disappointment after Victorian government rejects safe injecting room for CBD

StreetInsider.com – 22 April 2024

Monash experts: State Government rejection of a second supervised injecting room

ABC News – 18 April 2024

Woman's death at retreat raises safety questions over mushrooms and wellness products

ABC News Radio – 16 April 2024

Will psychedelic assisted therapy become more accessible?

Australian Journal of Pharmacy – 13 April 2024

Opioids, overdose and naloxone: starting the conversation

Honi Soit – 27 March 2024

War on youth: Rethinking festival drug use

The Canberra Times – 27 March 2024

Calls grow for poker machine reforms after gambler takes own life

The Canberra Times – 23 March 2024

Gambling with the future of the ACT's clubs - and punters

WA Today – 20 March 2024

Shannon is terminally ill. In a trailblazing trial, she took a white pill

ABC News – 15 March 2024

Roadside drug testing has been highlighted by a driver's false positive and loss of licence

Monash Lens – 28 February 2024

Psychedelics at Monash: World-first trials, therapist training, a feature documentary, and a proposed centre of excellence

Benzinga – 28 February 2-24

Psilocybin-assisted therapy achieves positive clinical trial results for treating generalized anxiety

Sydney Morning Herald – 17 February 2024

Medicinal cannabis, wonder drug or placebo?

ABC News Radio – 15 February 2024

Is it ok to share a glass of wine with your teenager?

The Age – 15 February 2024

\$205m drop in Pokies tax take tipped

Star Mail – 14 February 2024

Early intervention improves outcomes: How and why it's important to provide productive support for addiction

The Columns – 13 February 2024

Life after Fulbright

Gold Coast Bulletin – 10 February 2024

Signs of meth in 50 child deaths: Call for protection for siblings and others

Newsgroove – 10 February 2024

A 'raft of unanswered questions' remain as Australia's first psychedelic therapy clinic opens

Australian Pharmacist – 7 February 2024

Synthetic opioids 'one of the biggest threats' to drug-related harm

TV Central – 3 February 2024

Psychedelics: Stepping into the Unknown on SBS in late February

ABC News – 29 January 2024

Synthetic opioids like fentanyl could increase in Australia soon. Experts say we need to prepare now

The Canberra Times – 20 January 2024

Fentanyl lies in wait as ‘the wolf at Australia’s door’

Healthy Male – 19 December 2023

Understanding addiction to alcohol and other drugs

Healthy Male – 14 December 2023

Opioids in Australia – Is America’s epidemic our future?

Healthy Male – 12 December 2023

What men need to know about alcohol and mental health

Sydney Morning Herald – 9 December 2023

52 new makers of 2023

The Guardian – 29 November 2023

No evidence cannabis reduces long-term illicit opioids use, study finds

Irish Examiner – 29 November 2023

Study finds no evidence cannabis lowers long-term illicit opioid use

The Guardian – 26 November 2023

‘Playing us for years’: How pokies profits have funded tax-deductible spending within Australian clubs

ABC Radio – 20 November 2023

Discussing the cost of living crisis and gambling trends

Australian Pharmacist – 25 October 2023

7 things pharmacists need to know about off-label baclofen use

ABC Radio – 11 October 2023

How do we prevent young people from gambling?

Casino Guardian – 11 October 2023

Anti-gambling campaigners in Tasmania insist on introducing measures to tackle gambling harm ASAP

The Riotact – 8 October 2023

Former British Columbia paramedic offers expert insight into upcoming ACT drug decriminalisation

Medical Republic – 4 October 2023

We’re on the path to legal recreational cannabis

Casino Guardian – 22 September 2023

Poker machines remain among the most discussed issues in Australia’s legislative process

The Sydney Morning Herald – 16 September 2023

TGA flags prescription cannabis risks as pain experts claim lack of medical benefit

Momentum Media – 12 September 2023

Going for broke: The advisers stealing to feed gambling addictions

Dandenong Star Journal – 12 September 2023

Overdoses ‘preventable’

The Age – 6 September 2023

AFL clubs ‘trade on misery’ as \$40m is lost on pokies

Herald Sun – 5 September 2023

Alcohol and drugs key driver of emergency department admissions, study of Alfred Hospital shows

Australian Pharmacist – 4 September 2023

Preventing unintentional overdose from dangerous drug interactions

SBS News – 1 September 2023

Treating sleep issues may be an effective way to treat PTSD

ABC News – 26 August 2023

Crown Sydney casino left ‘high and dry’ after betting on lure of VIP gamblers, expert says

NZ Herald – 20 August 2023

Is NZ being left behind on gambling regulation?

Australian Financial Review – 18 August 2023

How taking MDMA with your partner could boost your relationship

The Guardian – 17 August 2023

University of Sydney gambling research centre bankrolled by casinos is ‘troubling’, experts say

ABC News – 26 July 2023

Australia legalises psychedelics to treat some mental health conditions, but therapists warn it is no miracle cure

IFLScience – 25 July 2023

Psilocybin has outstanding success treating anorexia nervosa in first very small trial

Monash Lens – 17 July 2023

Victoria cracks down on pokies, but supporters fear interest groups could hold the winning hand

WA Today – 16 July 2023

Andrews' sweeping pokies reforms aim to level a lopsided approach

ABC Local – 12 July 2023

Elder abuse, detention centre gag law and preventing gambling

ABC Compass – 12 July 2023

Psychedelics - Healing the spirit?

New Scientist – 11 July 2023

People who microdose LSD sleep an extra 24 mins the following night

ABC Radio 774 – 10 July 2023

Is treatment for heroin addiction in Victoria falling behind other states?

ABC Radio AM – 10 July 2023

National self-exclusion register for problem gamblers

The Age – 9 July 2023

Kids' parties became just another excuse to have a drink

SkyNews – 2 July 2023

Australia becomes first country to legalise medical psychedelics

Herald Sun – 2 July 2023

Program sees no drop in opioid script rates

Kyabram Free Press – 1 July 2023

World-first psychedelic treatment plan launches

The Sunday Project – 1 July 2023

Australia on alert for fentanyl epidemic that is killing Americans at record rates



OUR COLLABORATORS

Members of the Monash Addiction Research Centre collaborate with a diverse range of local, national and international research and clinical partners. The agencies listed below represent some of our key partnerships with research organisations, health services and community associations.

Alfred Health
Ambulance Victoria
Area 4 Pharmacotherapy Network
Association of Participating Service Users
Australian Institute of Family Studies
Australian National University
Australian Research Council
Barwon Health
Beyond Blue
Bouverie Centre
Burnet Institute
Cancer Council Victoria
Chisholm TAFE
Deakin University
Department of Health and Human Services, Victoria
Department of Health, Commonwealth
Eastern Health
Eastern Health Foundation
Eastern Melbourne PHN
Foundation for Alcohol Research and Education (FARE)
Harm Reduction Victoria
La Trobe University
Monash Health
National Centre for Education and Training on Addiction (NCETA), Flinders University
National Drug and Alcohol Research Centre (NDARC), University of New South Wales
National Drug Research Institute (NDRI), Curtin University
Nurses and Midwives Health Program Victoria
Penington Institute
Peninsula Health
Self Help Addiction Resource Centre (SHARC)
Leeds Trinity University, UK
St Vincent's Hospital, Melbourne
Turning Point
University of Melbourne
University of Newcastle
University of Oregon, USA
University of Queensland
University of Sydney
University of Tasmania
University of Wollongong
VicHealth
Victorian Alcohol and Drug Association (VAADA)
Victorian Responsible Gambling Foundation
Windana
World Health Organisation
Youth Support + Advocacy Service (YSAS)

PUBLICATIONS

1. Mathieson, S., **Collie, A.**, Maher, C.G., Shaheed, C.A., **Xia, T.**, Gilbert, S., Ferreira, G.E., **Di Donato, M.F.** Secular trends in gabapentinoid dispensing by compensated workers with low back pain: A retrospective cohort study. (2024) *Occupational and Environmental Medicine*, 81 (5), 245-251. DOI: 10.1136/oemed-2023-109369
2. Weeks, G.R., Gobarani, R.K., Abramson, M.J., Bonevski, B., Webb, A., Thomas, D., Paul, E., Sarwar, M.R., Smith, B.J., Perinpanathan, S., Kirska, S., Parkinson, J., Meanger, D., Coward, L., Rofe, O., Lee, P., Van Den Bosch, D., **George, J.** Varenicline and nicotine replacement therapy for smokers admitted to hospitals: A randomized clinical trial. (2024) *JAMA Network Open*, 7 (6), e2418120. DOI:10.1001/fjamanetworkopen.2024.18120.
3. Rushton, C.M., Kelly, P.J., Thomas, T., Beck, A.K., Townsend, C., Baker, A.L., **Manning, V.**, Argent, A., Deane, F.P., Hides, L., Hitsman, B., Velleman, R., Velleman, G., Larance, B. SMART Family and Friends: Feasibility and outcomes of a video-conference delivered intervention for families impacted by another's methamphetamine use. (2024) *Journal of Substance Use and Addiction Treatment*, 161, art. no. 209355. DOI: 10.1016/j.josat.2024.209355
4. Castle, J.W., Syrjanen, R., Di Rago, M., **Schumann, J.L.**, Greene, S.L., Glowacki, L.L., **Gerostamoulos, D.** Identification of clobromazolam in Australian emergency department intoxications using data-independent high-resolution mass spectrometry and the HighResNPS.com database. (2024) *Journal of Analytical Toxicology*, 48 (5), 273-280. DOI: 10.1093/jat/bkae012
5. **Jung, M.**, **Xia, T.**, **Illomaki, J.**, **Pearce, C.**, **Nielsen, S.** Opioid characteristics and nonopioid interventions associated with successful opioid taper in patients with chronic noncancer pain. (2024) *Pain*, 165 (6), 1327-1335. DOI: 10.1097/j.pain.00000000000003133
6. **Verdejo-Garcia, A.**, Berry, J., Caracuel, A., Copersino, M.L., Field, M., Garland, E.L., Lorenzetti, V., Malloy-Diniz, L., **Manning, V.**, Marceau, E.M., Pennington, D.L., Rezapour, T., Strickland, J.C., Wiers, R.W., Ekhtiari, H. Clinical translation of expert-endorsed cognitive rehabilitation interventions for substance use disorders. (2024) *World Psychiatry*, 23 (2), 299-301. DOI: 10.1002/wps.21126
7. **Grist, E.**, **Cheetham, A.**, Jackson, J., Wood, P., Lord, S., Pricolo, A., Armstrong, F., Morgan, K., Nguyen, C., Tran, T., **Nielsen S.** Clinical effectiveness of pharmacist administration of long-acting injectable buprenorphine: Findings from the EPIC-MATOD study. (2024) *Drug and Alcohol Review*, 43 (7), 1856-1858. DOI: 10.1111/dar.13856
8. **Karthikeyan, N.**, **Xia, T.**, **Nielsen, S.**, **Picco L.** Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia. (2024). *Drug and Alcohol Review*, 43 (5), 1305-1312. DOI: 10.1111/dar.13855
9. Patsouras, M., Cook, M., Pennay, A., Kuntsche, E., **Manning, V.**, He, Z., Riordan, B. Support for a browser plug-in blocking online alcohol imagery among Australian participants: A qualitative interview study. (2024) *Health Promotion Journal of Australia*, 35 (4), 1285-1294. DOI: 10.1002/hpja.863
10. **Peart, A.**, **Grigg, J.**, Greenwood, C., **Killian, J.**, **Ogeil, P.**, **Lubman, D.** The impact of the COVID-19 pandemic on calls to an alcohol and drug helpline in Victoria, Australia, for alcohol, methamphetamine and cannabis use concerns. (2024) *Drug and Alcohol Review*, 43 (7), 2065-2076. DOI: 10.1111/dar.13868
11. Trigg, J., Rich, J., Williams, E., Baker, A., Bauld, L., Borland, R., Bullen, C., Daghli, D., Dunlop, A., Gartner, C., Jacka, D., **Lubman, D.**, **Manning, V.**, McCrohan, R., Segan, C., Walker, N., Bonevski, B. A qualitative study of using nicotine products for smoking cessation after discharge from residential drug and alcohol treatment in Australia. (2024) *Drug and Alcohol Review*, 45 (5), 1116-1131. DOI: 10.1111/dar.13850

12. Zacher, A., Zimmermann, J., Cole, D.M., Friedli, N., Opitz, A., Baumgartner, M.R., Steuer, A.E., **Verdejo-Garcia, A.**, Stock, A.-K., Beste, C., Quednow, B.B. Chemical cousins with contrasting behavioural profiles: MDMA users and methamphetamine users differ in social-cognitive functions and aggression. (2024) *European Neuropsychopharmacology*, 83, 43-54. DOI: 10.1016/j.euroneuro.2024.04.010
13. Ralph, B., **Duncan, T., Roberts, S., Savic, M., Robards, B.**, Elliot, K. Drinking as affective labour: A discussion of Australian men working in hospitality and corporate workplaces. (2024) *Sociology of Health and Illness*, 46 (7), 1456-1476. DOI: 10.1111/1467.9566.13792
14. Clay, S., Wilkinson, Z., Ginley, M., **Arunogiri, S.**, Christmass, M., Membrey, D., MacCartney, O., Sutherland, R., Colledge-Frisby, S., Marshall, A.D., Nagle, J., Degenhardt, L., Farrell, M., McKetin, R. The reflections of health service providers on implementing contingency management for methamphetamine use disorder in Australia. (2024) *Drug and Alcohol Review*, 43 (5), 1313-1322. DOI: 10.1111/dar.13853
15. Harris, R., Kavaliotis, E., **Drummond, S.P.A.**, Wolkow, A.P. Sleep, mental health and physical health in new shift workers transitioning to shift work: Systematic review and meta-analysis. (2024) *Sleep Medicine Reviews*, 75, art. no. 101927. DOI: 10.1016/j.smr.2024.101927
16. **Naren, T., Cook, J.**, MacCartney, P. Direct induction onto high-dose long-acting injectable buprenorphine: A case series. (2024) *Australasian Psychiatry*, 32 (3), 238-241. DOI: 10.1177/10398562241237655
17. Myles, D., **Carter, A.**, Yücel, M., Bode, S. Losses disguised as wins evoke the reward positivity event-related potential in a simulated machine gambling task. (2024) *Psychophysiology*, 61 (6), art. no. e14541. DOI: 10.1111/psyp.14541
18. Petrie, K., Abramson, M.J., **George, J.** Smoking, respiratory symptoms, lung function and life expectancy: A longitudinal study of ageing. (2024) *Respirology*, 29 (6), 471-478. DOI: 10.1111/resp.14683
19. Duncan, Z., Ward, B., Kippen, R., **Dietze, P.**, Sutton, K. A narrative systematic review of associations and temporality between use of methamphetamine, ecstasy/MDMA, or cocaine with anxiety or depressive symptoms. (2024) *Addictive Behaviors*, 153, art. no. 107988. DOI: 10.1016/j.addbeh.2024.107988
20. Freichel, R., **Christensen, E.**, Mrkonja, L., de Jong, P.J., Cousijn, J., Franken, I., Yücel, M., **Lee, R.**, Veer, I.M., **Albertella, L.**, Wiers, R.W. Attentional biases and their association with substance-use-related problems and addictive behaviors: The utility of a gamified value-modulated attentional capture task. (2024) *Addictive Behaviors Reports*, 19, art. no. 100534. DOI: 10.1016/j.abrep.2024.100534
21. **Mendes, P.**, Taylor, R., Roche, S. How has the media framed the introduction of the supervised injecting room in Victoria? A comparison of editorials of The Age and Herald Sun 2017–2022. (2024) *Australian Journal of Social Issues*, 59 (2), 501-516. DOI: 10.1002/ajs4.302
22. **Tefera, Y.G.**, Gray, S., **Nielsen, S.**, Gelaw, A., **Collie, A.** Impact of prescription medicines on work-related outcomes in workers with musculoskeletal disorders or injuries: A systematic scoping review. (2024) *Journal of Occupational Rehabilitation*, 34 (2), 398-414. DOI: 10.1007/s10926-023-10138-y
23. **Mendes, P.** “The most significant child welfare reform in a generation”: An examination of the strategies used by the Home Stretch campaign. (2024) *Australian Journal of Social Issues*, 59 (2), 328-343. DOI: 10.1002/ajs4.288
24. Turner, J.P., Halme, A.S., Caetano, P., **Langford, A.**, Tannenbaum, C. Government direct-to-consumer education to reduce prescription opioid use: A cluster randomized clinical trial. (2024) *JAMA Network Open*, 7 (5), p. E2413698. DOI: 10.1001/jamanetworkopen.2024.13698
25. Liu, C., Rotaru, K., Ren, L., Chamberlain, S.R., **Christensen, E.**, Brierley, M.-E., Richardson, K., **Lee, R.S.C.**, **Segrave, R.**, Grant, J.E., Kayayan, E., Hughes, S., Fontenelle, L.F., Lowe, A., Suo, C., Freichel, R., Wiers, R.W., Yücel, M., **Albertella, L.** Examining the unique relationships between problematic use of the internet and impulsive and compulsive tendencies: Network approach. (2024) *British Journal of Psychiatry Open*, 10 (3), art. no. e104. DOI: 10.1192/bjo.2024.59
26. FitzGerald, G., MacCartney, P., **Cook, J.**, Crawford, S., **Naren, T.** Time for Australia to increase take away doses in opioid agonist treatment. (2024) *International Journal of Drug Policy*, 127, art. no. 104420. DOI: 10.1016/j.drugpo.2024.104420.

27. Barnett, A., Pienaar, K., **Lubman, D.I., Arunogiri, S., Phan, V.**, Hayes, V., Lintzeris, N., **Savic, M.** The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences. (2024) *International Journal of Drug Policy*, 127, art. no. 104399. DOI: 10.1016/j.drugpo.2024.104399
28. Farrell, M., Shahbazi, J., Chambers, M., Byrne, M., Gholami, J., Zahra, E., Grebely, J., Lintzeris, N., Larance, B., Ali, R., **Nielsen, S.**, Dunlop, A., Dore, G.J., McDonough, M., Montebello, M., Weiss, R., Rodgers, C., **Cook, J.**, Degenhardt, L., CoLAB study team. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. (2024) *International Journal of Drug Policy*, 127, art. no. 104390. DOI: 10.1016/j.drugpo.2024.104390
29. Carey, R.N., Crawford, G., Jancey, J., **Lam, T.**, Nimmo, L., Trapp, G., Pollard, C., Hooper, P., Leavy, J.E. Young people's alcohol use in and around water: A scoping review of the literature. (2024) *Drug and Alcohol Review*, 43 (4), 874-896. DOI: 10.1111/dar.13831
30. Bolt, G.L., Piercy, H., Bradshaw, J., **Manning, V.** Smartphone-delivered approach bias modification for reducing harmful drinking amongst middle-older age adults: Secondary analyses of a single-arm pilot study. (2024) *Drug and Alcohol Review*, 43 (4), 956-968. DOI: 10.1111/dar.13827
31. Mahlberg, J., Giddens, E., Tiego, J., Bellgrove, M., Fornito, A., **Verdejo-Garcia, A.** Common genetic factors for uncontrolled eating mechanisms. (2024) *International Journal of Eating Disorders*, 57 (5), 1224-1233. DOI: 10.1002/eat.24179
32. **Naren, T., Cook, J.**, MacCartney, P., Membrey, D. Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine. (2024) *Drug and Alcohol Review*, 43 (4), 1013-1018. DOI: 10.1111/dar.13826
33. Prior, K., Salemink, E., Piggott, M., **Manning, V.**, Wiers, R., Teachman, B., Teesson, M., Baillie, J., Mahoney, A., McLellan, L., Newton, N., Stapinski, A. Web-based cognitive bias modification program for young people with social anxiety and hazardous alcohol use: Feasibility, acceptability, and preliminary efficacy study. (2023) *JMIR Formative Research*, 7, e46008. DOI: 10.2196/46008
34. **Anderson, A., Verdejo-Garcia, A.** Cognitive remediation for impulsivity in addictive disorders: Review of current evidence and future directions. (2023) *Current Addiction Reports*, 10, 472-484. DOI: 10.1007/s40429-023-00504-4
35. Wardle, F., Piatkowski, T., Clifford, S., Peacock, A., **Dietze, P.**, Lim, M., Douglass, C., Hill, P., Moore, S., Miller, M., Brett, J. Wright, C. Safe beats down under: Investigating the support of drug checking at a regional festival in the Northern Territory, Australia. (2024) *Drugs: Education, Prevention and Policy*, 1-9. DOI: 10.1080/09687637.2024.2330938
36. **Tefera Y., Di Donato, M.**, Sheehan, L., Gray, S., **Nielsen, S., Xia, T., Collie A.** Capture, coding and reporting of healthcare and medicine information in Australian workers' compensation systems. (2024) *Journal of Occupational and Environmental Medicine*, 66 (5), e213-e221. DOI: 10.1097/JOM.0000000000003084
37. Scott, D., McGrath, M., **Beard, N., Chislett, S., Baldwin, R., Nehme, Z., Lubman, D.I., Ogeil, R.P.** Adolescent suicidal behaviors during the COVID-19 pandemic in Australia: Analysis of acute harms assessed via ambulance data. (2024) *Journal of Adolescent Health*, 74 (5), 908-915. DOI: 10.1016/j.jadohealth.2023.12.022
38. Lau, G., Ang, J.Y., Kim, N., Gabbe, B.J., Mitra, B., **Dietze, P.M.**, Reeder, S., **Beck, B.** Approaches and reporting of alcohol and other drug testing for injured patients in hospital-based studies: A systematic review. (2024) *Drug and Alcohol Review*, 43 (4), 897-926. DOI: 10.1111/dar.13816
39. Avram, M., Müller, F., Preller, K.H., **Razi, A.**, Rogg, H., Korda, A., Holze, F., Vizeli, P., Ley, L., Liechti, M.E., Borgwardt, S. Effective connectivity of thalamocortical interactions following d-Amphetamine, LSD, and MDMA administration. (2024) *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 9 (5), 522-532. DOI: 10.1016/j.bpsc.2023.07.010

40. Price, O., **Dietze, P.**, Maher, L., Dore, G.J., Sutherland, R., Salom, C., Bruno, R., Crawford, S., Degenhardt, L., Larney, S., Peacock, A. High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs. (2024) *Vaccine*, 42 (11), 2877-2885. DOI: 10.1016/j.vaccine.2024.03.051
41. **Jung, M., Xia, T., Iloma, J., Pearce, C., Nielsen, S.** Trajectories of prescription opioid tapering in patients with chronic non-cancer pain: A retrospective cohort study, 2015–2020. (2024) *Pain Medicine (United States)*, 25 (4), 263-274. DOI: 10.1093/pm/pnae002
42. **Nielsen, S., Xia, T.** Interventions for reducing the prescribing of pharmaceutical opioids in Australia: Are they effectively reducing opioid harm? (2024) *Medical Journal of Australia*, 220 (6), 311-312. DOI: 10.5694/mja2.52259
43. Rezapour, T., Rafei, P., Baldacchino, A., Conrod, P.J., Dom, G., Fishbein, D.H., Kazemi, A., Hendriks, V., Newton, N., Riggs, N.R., Squeglia, L.M., Teesson, M., Vassileva, J., **Verdejo-Garcia, A.**, Ekhtiari, H. Neuroscience-informed classification of prevention interventions in substance use disorders: An RDoC-based approach. (2024) *Neuroscience and Biobehavioral Reviews*, 159, art. no. 105578. DOI: 10.1016/j.neubiorev.2024.105578
44. Sekula, A., Puspanathan, P., Downey, L., **Liknaitzky, P.** Producing altered states of consciousness, reducing substance misuse: A review of psychedelic-assisted psychotherapy, transcendental meditation and hypnotherapy. (2024) *Psychoactives*, 3 (2), 137-166. DOI: 10.3390/psychoactives3020010
45. **Nielsen, S.**, Stowe, M.J., Ritter, A. In pursuit of safer supply: An emerging evidence base for medical and nonmedical models. (2024) *International Journal of Drug Policy*, 126, art. no. 104365. DOI: 10.1016/j.drugpo.2024.104365
46. Lee, Y.Y., Slade, T., Chatterton, M.L., **Le, L.K.-D.**, Perez, J.K., Faller, J., Chapman, C., Newton, N.C., Sunderland, M., Teesson, M., Mihalopoulos, C. Age at first drink and its influence on alcohol use behaviours in young adulthood: Evidence from an Australian household-based panel study. (2024) *Preventive Medicine*, 181, art. no. 107898. DOI: 10.1016/j.ypmed.2024.107898
47. Lancaster, K., Gendera, S., Treloar, C., Rhodes, T., Shahbazi, J., Byrne, M., **Nielsen, S.**, Degenhardt, L., Farrell, M. Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence. (2024) *International Journal of Drug Policy*, 126, art. no. 104359. DOI: 10.1016/j.drugpo.2024.104359
48. **Xia, T., Picco, L., Buchbinder, R., Haas, R., Nielsen, S.** Association of state-level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia. (2024) *British Journal of Clinical Pharmacology*, 90 (4), 1162-1172. DOI: 10.1111/bcp.15996
49. Skinner, J.A., Leary, M., Whatnall, M., Collins, R.A., Pursey, K.M., **Verdejo-Garcia, A.**, Hay, P.J., Baker, A.L., Hides, L., Paxton, S.J., Wood, L.G., Colyvas, K., Collins, C.E., Burrows, T.L. A three-arm randomised controlled trial of a telehealth intervention targeting improvement in addictive eating for Australian adults (the TRACE program). (2024) *Appetite*, 195, art. no. 107211. DOI: 10.1016/j.appet.2024.107211
50. Savaglio, M., **Yap, M.**, Vincent, A., Skouteris, H. Mapping community-based youth mental health services in Tasmania, Australia. (2024) *Australian Journal of Primary Health*, 30 (2), art. no. PY23074. DOI: 10.1071/PY23074
51. Moullin, J.C., Staniland, L., Uren, H., **Nielsen, S.**, Lenton, S. Advancing the implementation of take-home naloxone by community pharmacists: Testing the role of COM-B. (2024) *Drug and Alcohol Review*, 43 (3), 746-759. DOI: 10.1111/dar.13805
52. Maclsaac, M.B., Whitton, B., Anderson, J., Cogger, S., Vella-Horne, D., Penn, M., Weeks, T., Elmore, K., Pemberton, D., Winter, R.J., Papatuca, T., Howell, J., Hellard, M., **Stoové, M.**, Wilson, D., Pedrana, A., Doyle, J.S., **Clark, N.**, Holmes, J.A., Thompson, A.J. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility. (2024) *International Journal of Drug Policy*, 125, art. no. 104317. DOI: 10.1016/j.drugpo.2024.104317
53. **Selamoglu, M.**, Erbas, B., Wilson, H., **Barton, C.** 'Why do we have to be the gatekeepers?' Australian general practitioners' knowledge, attitudes and prescribing intentions on e-cigarettes as a smoking cessation aid. (2024) *BMC Primary Care*, 25, 53. DOI 10.1186/s12875-024-02292

54. Woolley, J., **Savic, M., Garfield, J.B.B., Petukhova, R., Manning, V., Lubman, D.I.**, Barnett, A. Experiences of telehealth among people receiving alcohol and other drug treatment during the COVID-19 pandemic: Implications for future telehealth delivery. (2024) *Drug and Alcohol Review*, 43 (3), 694-704. DOI: 10.1111/dar.13797
55. Chan, J., Ward, B., Maher, L., Crawford, S., **Stoové, M., Dietze, P.** Parents who inject drugs: Demographics, care arrangements and correlates for child placement in out-of-home care. (2024) *Drug and Alcohol Review*, 43 (3), 775-786. DOI: 10.1111/dar.13798
56. O'Keefe, D., Jacka, D., Douglass, C., Gunn, J., **Stoove, M., Crawford, S., Bryant, M., Higgs, P., Dietze, P., Hellard, M.** Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines: Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia. (2024) *Journal of Viral Hepatitis*, 31 (3), 151-155. DOI: 10.1111/jvh.13909
57. **Christensen, E., Albertella, L.,** Chamberlain, S.R., Brydevall, M., Suo, C., Grant, J.E., Yücel, M., **Lee, R.S.C.** The neurocognitive correlates of non-substance addictive behaviors. (2024) *Addictive Behaviors*, 150, art. no. 107904. DOI: 10.1016/j.addbeh.2023.107904
58. **Dietze, P.,** Stewart, A., Hill, P., Draper, B., **Curtis, M.,** Kirwan, A. The National Naloxone Reference Group: A collective voice on take-home naloxone policy and practice in Australia. (2024) *Drug and Alcohol Review*, 43 (3), 685-687. DOI: 10.1111/dar.13771
59. Cerocchi, N., Mojica-Perez, Y., Livingston, M., **Arunogiri, S.,** Pennay, A., Callinan, S. Examining the association between psychological distress and alcohol use in Australian adolescents over a period of declining consumption. (2024) *Drug and Alcohol Review*, 43 (3), 633-642. DOI: 10.1111/dar.13703
60. Baker, A.L., McCarter, K., Turner, A., Segan, C., Castle, D., Brophy, L., Borland, R., Kelly, P.J., Bonevski, B., Baird, D., Filia, S., Attia, J., Szwec, S., Palazzi, K., White, S.L., Williams, J.M., Wrobel, A.L., Ireland, A., Saxby, K., Ghijben, P., **Petrie, D.,** Sweeney, R. 'Quitlink': Outcomes of a randomised controlled trial of peer researcher facilitated referral to a tailored quitline tobacco treatment for people receiving mental health services. (2024) *Australian and New Zealand Journal of Psychiatry*, 58 (3), 260-276. DOI: 10.1177/00048674231181039
61. Matar, J.L., Laletas, S., **Lubman, D.I.** Mental health concerns and help-seeking behaviors among adolescents in high socioeconomic status groups: A scoping review. (2024) *Adolescent Research Review*, 9 (1), 93-134. DOI: 10.1007/s40894-023-00214-y
62. **Mendes, P.** From welfarist support for vulnerable groups to a social justice perspective: The Australian Council of Social Service and the construction of poverty, 1956–75. (2024) *Australian Journal of Politics and History*, 70 (1), 40-60. DOI: 10.1111/ajph.12869
63. Myles, D., **O'Brien, K.,** Yücel, M., **Carter, A.** Three contrasting accounts of electronic gambling machine related harm: Impacts on community views towards gambling policy and responsibility. (2024) *Journal of Gambling Studies*, 40 (1), 29-49. DOI: 10.1007/s10899-023-10206-1
64. **Peart A., Horn F., Rowland B., Arunogiri S.,** Jones D., **Manning V., Lubman, D.** Peer navigation: A pilot study to improve recovery capital for alcohol and other drug telephone helpline callers. (2024) *Drugs: Education, Prevention and Policy*, 1–11. DOI: 10.1080/09687637.2024.2330941
65. Cameron, L., **Ride, J.,** Devlin, N. An economic model of gambling behaviour: A two-stage approach. (2024) *Journal of Gambling Studies*, 40 (1), 65-81. DOI: 10.1007/s10899-022-10146-2
66. **Curtis, L., Roberts, S.** Exploring alcohol cultures and homosocial relationships in women's amateur AFL teams. (2024) *Journal of Sociology*, 60 (1), 59-78. DOI: 10.1177/14407833221093398
67. Ball, J., **Nehme, Z.,** Stub, D. At an intersection of public health crises: Drugs, a pandemic, and out-of-hospital cardiac arrest. (2024) *Resuscitation*, 195, art. no. 110127. DOI: 10.1016/j.resuscitation.2024.110127
68. **Baldwin, R.,** Miller, P.G., Coomber, K., Scott, D., Paradies, Y. Impacts of Northern Territory banned drinker register on police recorded youth assault. (2024) *Drug and Alcohol Review*, 43 (2), 529-538. DOI: 10.1111/dar.13804
69. McCoy, J., **Nielsen, S.,** Bruno, R. Development and validation of a brief screening tool for over-the-counter codeine dependence. (2024) *Research in Social and Administrative Pharmacy*, 20 (2), 182-189. DOI: 10.1016/j.sapharm.2023.11.002

70. Clifford, S., Wright, C.J.C., Miller, P.G., **Baldwin, R.**, Griffiths, K.E., Smith, J.A., Livingston, M. Police-recorded adult sexual assault in the Northern Territory, Australia: Alcohol involvement and alcohol policy effects. (2024) *Drug and Alcohol Review*, 43 (2), 519-528. DOI: 10.1111/dar.13787
71. Coomber, K., **Baldwin, R.**, Taylor, N., Callinan, S., Wilkinson, C., Toumbourou, J.W., Chikritzhs, T., Miller, P.G. Characteristics of high- and low-risk drinkers who use online alcohol home delivery in Western Australia. (2024) *Drug and Alcohol Review*, 43 (2), 407-415. DOI: 10.1111/dar.13783
72. Newall, P., Allami, Y., Andrade, M., Ayton, P., Baker-Frampton, R., **Bennett, D.**, Browne, M., Bunn, C., Bush-Evans, R., Chen, S., Collard, S., De Jans, S., Derevensky, J., Dowling, N.A., Dymond, S., Froude, A., Goyder, E., Heirene, R.M., Hing, N., Hudders, L., Hunt, K., James, R.J.E., Li, E., Ludvig, E.A., Marionneau, V., McGrane, E., Merkouris, S.S., Orford, J., Parrado-González, A., Pryce, R., Rockloff, M., Romild, U., Rossi, R., Russell, A.M.T., Singmann, H., Quosai, T.S., Stark, S., Suomi, A., Swanton, T.B., Talberg, N., Thoma, V., Torrance, J., Tulloch, C., van Holst, R.J., Walasek, L., Wardle, H., West, J., Wheaton, J., Xiao, L.Y., Young, M.M., Bellringer, M.E., Sharman, S., Roberts, A. 'No evidence of harm' implies no evidence of safety: Framing the lack of causal evidence in gambling advertising research. (2024) *Addiction*, 119 (2), 391-396. DOI: 10.1111/add.16369
73. Michell, E., **Lam, T.**, **Xia, T.**, **Nielsen, S.**, Stevens, J. The relationship between presurgical opioid type and persistent postoperative opioid use: A retrospective observational linkage study comparing tapentadol and oxycodone. (2024) *Anaesthesia*, 79 (2), 203-205. DOI: 10.1111/anae.16164
74. Higginbotham, B., Perez, J.K., Louie, E., Haber, P.S., **Lubman, D.**, **Arunogiri, S.**, Chatterton, M.L., Morley, K.C. Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder. (2024) *Australian and New Zealand Journal of Psychiatry*, 58 (2), 117-133. DOI: 10.1177/00048674231201541
75. McGrath, M., Stare, M., Chua, P., **Ogeil, R.**, **Nehme, Z.**, Scott, D., **Lubman, D.I.** Opioid-related ambulance attendances during the first 2 years of the COVID-19 pandemic in Victoria, Australia. (2024) *Addiction*, 119 (2), 348-355. DOI: 10.1111/add.16360
76. Lau, G., Mitra, B., Gabbe, B.J., **Dietze, P.M.**, Reeder, S., Cameron, P.A., Smit, D.V., Schneider, H.G., Symons, E., Koolstra, C., Stewart, C., **Beck, B.** Prevalence of alcohol and other drug detections in non-transport injury events. (2024) *Emergency Medicine Australasia*, 36 (1), 78-87. DOI: 10.1111/1742-6723.14312
77. Mattingley, S., Youssef, G.J., Graeme, L., Sloan, E., **Manning, V.**, Hall, K. Negative urgency, distress tolerance, and symptoms of substance use, eating, and borderline personality disorders in treatment-seeking young people. (2024) *Journal of Clinical Psychology*, 80 (2), 261-278. DOI: 10.1002/jclp.23579
78. Duncan, Z., Kippen, R., Sutton, K., Ward, B., Quinn, B., **Dietze, P.** Health service use for mental health reasons in a cohort of people who use methamphetamine experiencing moderate to severe anxiety or depression. (2024) *International Journal of Mental Health and Addiction*, 22 (1), 543-559. DOI: 10.1007/s11469-022-00889-9
79. **Hall, N.Y.**, Hetti Pathirannahalage, D.M., Mihalopoulos, C., Austin, S.B., Le, L. Global prevalence of adolescent use of nonprescription weight-loss products: A systematic review and meta-analysis. (2024) *JAMA Network Open*, 7 (1), E2350940. DOI: 10.1001/jamanetworkopen.2023.50940
80. Tas, B., Lawn, W., Jauncey, M., Bartlett, M., **Dietze, P.**, O'Keefe, D., **Clark, N.**, Henderson, B., Cowan, C., Meredith, O., Strang, J. Overdose detection among high-risk opioid users via a wearable chest sensor in a supervised injecting facility: Protocol for an observational study. (2024) *JMIR Research Protocols*, 13, art. no. e57367. DOI: 10.2196/57367
81. Syrjanen, R., **Schumann, J.L.**, Castle, J.W., Sharp, L., Griffiths, A., Blakey, K., Dutch, M., Maplesden, J., Greene, S.L. Protonitazene detection in two cases of opioid toxicity following the use of tetrahydrocannabinol vape products in Australia. (2024) *Clinical Toxicology*, 62 (8), 539-541. DOI: 10.1080/15563650.2024.2383692

82. **Peart, A., Horn, F., Petukhova, R.,** Barnett, A., **Lubman, D.I.** Web-based forums for people experiencing substance use or gambling disorders: Scoping review. (2024) *JMIR Mental Health*, 11, art. no. e49010. DOI: 10.2196/49010
83. Greene, S.L., Syrjanen, R., Hodgson, S.E., Abouchedid, R., **Schumann, J.** Co-exposure to gamma-hydroxybutyrate is associated with attenuated neuropsychiatric and stimulant effects of metamfetamine. (2024) *Clinical Toxicology*, 62 (5), 303-313. DOI: 10.1080/15563650.2024.2353265
84. Gunatillaka, N., Tam, C.W.M., Ngo, K., **Sturgiss, E.** Heavy drinkers' expectations and experiences when discussing alcohol use during a general practice visit in Australia: A qualitative study. (2024) *Australian Journal of General Practice*, 53 (6), 403-407. DOI: 10.31128/AJGP-08-23-6952
85. Wilkes, R., Roberts, D.M., **Liknaitzky, P.,** Brett, J. The psychedelic call: Analysis of Australian Poisons Information Centre calls associated with classic psychedelics. (2024) *Clinical Toxicology*, 62 (4), 242-247. DOI: 10.1080/15563650.2024.2346612
86. Melby, K., Farokhnia, M., Tolomeo, S., Bhad, R., Bramnes, J.G., Baldacchino, A., Rao, R., Kandasami, G., Butner, J.L., **Phan, V.,** Fonseca, F., Rafei, P., Long, J., Tzeferakos, G., Dom, G. International perspectives on opioid use disorder and treatment: Results from an online convenience sample. (2024) *Heroin Addiction and Related Clinical Problems*, 26 (1), art. no. 5. DOI: 10.62401/2531-4122-2024-5
87. Ekhtiari, H., Khojasteh Zonoozi, A., Rafei, P., Abolghasemi, F.S., Pemstein, D., Abdelgawad, T., Achab, S., Ghafri, H.A., Al'Absi, M., Bisch, M., Conti, A.A., Ambekar, A., **Arunogiri, S.,** Bhad, R., Bilici, R., Brady, K., Bunt, G., Busse, A., Butner, J.L., Danesh, A., El-Khoury, J., Omari, F.E., Jokūbonis, D., Jong, C.D., Dom, G., Ebrahimi, M., Fathi Jouzdani, A., Ferri, M., Galea-Singer, S., Parker, D.G., Higuchi, S., Kathiresan, P., Khelifa, E., Kouimtsidis, C., Krupitsky, E.M., Long, J., Maremmani, I., McGovern, G., Mohaddes Ardabili, H., Rahimi-Movaghar, A., Rataemane, S.T., Sangchooli, A., Sibeko, G., Vella, A.M., Vista, S.B.D., Zare-Bidoky, M., Zhao, M., Javed, A., Potenza, M.N., Baldacchino, A.M. World addiction medicine reports: Formation of the International Society of Addiction Medicine Global Expert Network (ISAM-GEN) and its global surveys. (2024) *Frontiers in Psychiatry*, 15, art. no. 1230318. DOI: 10.3389/fpsy.2024.1230318
88. Bush, R., Staiger, P.K., McNeill, I.M., Brown, R., Orellana, L., **Lubman, D.,** McNair, R. Evaluation of an SMS based alcohol intervention for same sex attracted women: A randomized controlled trial to examine feasibility, acceptability, and efficacy. (2024) *Substance Use & Misuse*, 59 (8), 1157-1166. DOI: 10.1080/10826084.2024.2321257
89. Hearps, A.C., Vootukuru, N., Ebrahimnezhaddarzi, S., Harney, B.L., Boo, I., Nguyen, L., Pavlyshyn, D., **Dietze, P.M.,** Drummer, H.E., Thompson, A.J., Jaworowski, A., Hellard, M.E., Sacks-Davis, R., **Doyle, J.S.** Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy. (2024) *Frontiers in Immunology*, 15, art. no. 1352440. DOI: 10.3389/fimmu.2024.1352440
90. Chavulak, J., Smyth, T., Sutcliffe, N., **Petrakis, M.** Staff perspectives in mental health research regarding restrictive interventions: An Australian scoping review and thematic analysis. (2024) *Behavioral Sciences*, 14 (1), art. no. 9. DOI: 10.3390/bs14010009
91. **Kroes, S.,** McKim, H., **Petrakis, M.** Workforce perspectives of sustaining the utilisation of a harm reduction instrument in a mental health residential setting. (2024) *Healthcare (Switzerland)*, 12 (2), art. no. 276. DOI: 10.3390/healthcare12020276
92. Anderson, A., Giddens, E., Tiego, J., **Lubman, D., Verdejo-Garcia, A.** Leveraging online treatment to re-examine the association between alcohol use and disinhibition [Tratamiento Online Como Plataforma Para Re-examinar la Relación Entre el Uso de Alcohol y la Desinhibición Cognitiva]. (2024) *Psicothema*, 36 (1), 15-25. DOI: 10.7334/psicothema2022.516
93. **Langford, A.V.,** Schneider, C.R., Reeve, E., Doctor, J.N., Gnjjidic, D. Comment on: "Patient perceptions of opioids and benzodiazepines and attitudes toward deprescribing". (2024) *Drugs and Aging*, 41 (1), 77-78. DOI: 10.1007/s40266-023-01086-6
94. Robinson, A.H., Mahlberg, J., Chong, T.T.J., **Verdejo-Garcia, A.** Model-based and model-free mechanisms in methamphetamine use disorder. (2024) *Addiction Biology*, 29 (1), art. no. e13356. DOI: 10.1111/adb.13356

95. **Langford, A.V.**, Bero, L., Lin, C.-W.C., Blyth, F.M., Doctor, J.N., Holliday, S., Jeon, Y.-H., Moullin, J.C., Murnion, B., **Nielsen, S.**, Penm, J., Reeve, E., Reid, S., Wale, J., Osman, R., Gnjidic, D., Schneider, C.R. Context matters: Using an Evidence to Decision (EtD) framework to develop and encourage uptake of opioid deprescribing guideline recommendations at the point-of-care. (2024) *Journal of Clinical Epidemiology*, 165, art. no. 111204. DOI: 10.1016/j.jclinepi.2023.10.020
96. Santamarina, R., Caldicott, D., Fitzgerald, J., **Schumann, J.L.** Drug-related deaths at Australian music festivals. (2024) *International Journal of Drug Policy*, 123, art. no. 104274. DOI: 10.1016/j.drugpo.2023.104274
97. Attwood, L.O., O’Keefe, D., Higgs, P., Vujovic, O., **Doyle, J.S.**, Stewardson, A.J. Epidemiology of acute infections in people who inject drugs in Australia. (2024) *Drug and Alcohol Review*, 43 (1), 304-314. DOI: 10.1111/dar.13772
98. **Haines, S., Savic, M., Carter, A.** Healthcare providers beliefs about the meanings and impacts of prescription drug monitoring program alerts. (2024) *Addiction Research and Theory*, 32 (5), pp. 325-332. DOI: 10.1080/16066359.2023.2271833
99. Perales, J.C., Flayelle, M., **Verdejo-García, A.**, Clark, L., Billieux, J. Cognitive, computational and learning processes involved in behavioral addiction: Current views and future directions. (2024) *Addictive Behaviors*, 148, art. no. 107874. DOI: 10.1016/j.addbeh.2023.107874
100. Jones, J.A., Belin-Rauscent, A., **Jupp, B.**, Fouyssac, M., Sawiak, S.J., Zuhlsdorff, K., Zhukovsky, P., Hebdon, L., Velazquez Sanchez, C., Robbins, T.W., Everitt, B.J., Belin, D., Dalley, J.W. Neurobehavioral precursors of compulsive cocaine seeking in dual frontostriatal circuits. (2024) *Biological Psychiatry Global Open Science*, 4 (1), 194-202. DOI: 10.1016/j.bpsgos.2023.06.001
101. Hew, A., **Arunogiri, S.** Zero alcohol, but not zero risk? (2024) *Australian and New Zealand Journal of Psychiatry*, 58 (1), 10-11. DOI: 10.1177/00048674231200399
102. **Arunogiri, S., Manning, V.** The impact of a continuum model of alcohol problems on clinical practice: A double-edged sword? Commentary on Morris et al. ‘Should we promote alcohol problems as a continuum? Implications for policy and practice’. (2024) *Drugs: Education, Prevention and Policy*, 31 (2), 284-286. DOI: 10.1080/09687637.2023.2244144
103. **Roxburgh, A.D.**, Best, D., **Lubman, D.I., Manning, V.** Composition of social networks to build recovery capital differ across early and stable stages of recovery. (2024) *Addiction Research and Theory*, 32 (3), 186-193. DOI: 10.1080/16066359.2023.2238594
104. **Mantiniaks, D.**, Parsons, S., **Schumann, J., Drummer, O.**, Baber, Y., Archer, M., Gerostamoulos, D. A retrospective review of methylamphetamine detected in child deaths reported to the Victorian Coroner, Australia. (2024) *Forensic Science, Medicine and Pathology*, 20, 1261-1267. DOI: 10.1007/s12024-024-00778-8
105. Cheng, C.H.J., **Langford, A.V.**, Gnjidic, D., Farrell, B.J., Schneider, C.R. Survey content validation evaluating the dissemination and implementation of deprescribing guidelines. (2024) *Basic and Clinical Pharmacology and Toxicology*, 134 (1), 63-71. DOI: 10.1111/bcpt.13922
106. Rubenis, A.J., Barnett, A.I., **Arunogiri, S.** Keeping clients connected: Exploring Australian alcohol and other drug clinicians’ perspectives on barriers and facilitators to treatment attendance. (2024) *Addiction Research and Theory*, 32 (2), 120-128. DOI: 10.1080/16066359.2023.2227092
107. Maplesden, J., Greene, S., Syrjanen, R., Di Rago, M., **Schumann, J.** An intoxication involving 2-methyl AP-237 and AP-238 from Victoria, Australia: Case report. (2024) *Drug Testing and Analysis*, 16 (1), 93-98. DOI: 10.1002/dta.3524
108. **Peart, A., Horn, F., Manning, V.**, Campbell, R., **Lubman, D.I.** The experiences of family members attending an online addiction education program: A qualitative study. (2024) *Drugs: Education, Prevention and Policy*, 31 (3), 310-317. DOI: 10.1080/09687637.2023.2184248
109. Berryman, B., Niesen, R., Higgs, P., **Dietze, P.**, Stewart, A., Cossar, R., Walker, S. Experiences of participation in a longitudinal cohort study of people who inject drugs in Victoria, Australia. (2024) *Drugs: Education, Prevention and Policy*, 31 (2), 229-238. DOI: 10.1080/09687637.2023.2177523
110. Lau, G., Ang, J.Y., Kim, N., Gabbe, B.J., Mitra, B., **Dietze, P.M.**, Reeder, S., Scott, D., **Beck, B.** Prevalence of alcohol and other drug use in patients presenting to hospital for violence-related injuries: A systematic review. (2024) *Trauma, Violence, and Abuse*, 25 (1), 306-326. DOI: 10.1177/15248380221150951

111. Raggatt, M., Douglass, C., Wright, C., Reddan, H., O'Connell, H., **Dietze, P.**, Lim, M. Music festival attendees' transport mode and beliefs about alcohol and illicit drug use before driving in Victoria, Australia. (2024) *Drugs: Education, Prevention and Policy*, 31 (1), 139-147. DOI: 10.1080/09687637.2022.2117020
112. **Searby, A.**, Burr, D., Redley, B. The impact of COVID-19 on nurse alcohol consumption: A qualitative exploration. (2024) *Journal of Clinical Nursing*, 33 (1), 368-380. DOI: 10.1111/jocn.16467
113. **Stoliker, D.**, Novelli, L., Vollenweider, F., Egan, G., Preller, K., Razi, A. Neural mechanisms of resting-state networks and the amygdala underlying the cognitive and emotional effects of psilocybin. (2024) *Biological Psychiatry*, 96 (1), 57-66. DOI: 10.1016/j.biopsych.2024.01.002
114. Elkholly, H., Tay Wee Teck, J., **Arunogiri, S.**, Ramses Asaad, M., Baessler, F., Bhad, R., Borghi, E.N., Busse, A., Ekhtiari, H., Dave, S., Ferri, M., Greene, C., Koob, G.F., Kouimtsidis, C., Krupchanka, D., Nikendei, C., Pipyrou, S., Poznyak, V., Volkow, N.D., White, A.M., Zonoozi, A.K., Ezard, N., Potenza, M.N., Baldacchino, A.M. Substance use disorders among forcibly displaced people: A narrative review. (2023) *Current Addiction Reports*, 10, 341-352. DOI: 10.1007/s40429-023-00467-6
115. Zühlsdorff, K., Verdejo-Román, J., Clark, L., Albein-Urios, N., Soriano-Mas, C., Cardinal, R.N., Robbins, T.W., Dalley, J.W., **Verdejo-García, A.**, Kanen, J.W. Computational modelling of reinforcement learning and functional neuroimaging of probabilistic reversal for dissociating compulsive behaviours in gambling and cocaine use disorders. (2023) *British Journal of Psychiatry Open*, 10 (1), art. no. e8. DOI: 10.1192/bjo.2023.611
116. **Grigg, J., Manning, V., Lubman, D.I.** A brief intervention for improving alcohol literacy and reducing harmful alcohol use by women attending a breast screening service: A randomised controlled trial. (2023) *Medical Journal of Australia*, 219 (11), 560. DOI: 10.5694/mja2.52161
117. **Mantiniaks, D.**, Di Rago, M., **Drummer, O.**, Glowacki, L., **Schumann, J., Gerostamoulos, D.** Quantitative analysis of tetrahydrocannabinol isomers and other toxicologically relevant drugs in blood. (2023) *Drug Testing and Analysis*, 16 (10), 1102-1112. DOI: 10.1002/dta.3632
118. Dawe, J., Hughes, M., Christensen, S., Walsh, L., Richmond, J.A., Pedrana, A., Wilkinson, A.L., Owen, L., **Doyle, J.S.** Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: A mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022. (2023) *BMC Public Health*, 23 (1), art. no. 2289. DOI: 10.1186/s12889-023-17066-9
119. Syrjanen, R., **Schumann, J.L.**, Lyons, T., McKinnon, G., Hodgson, S.E., Abouchedid, R., **Gerostamoulos, D.**, Koutsogiannis, Z., Fitzgerald, J., Greene, S.L., EDNAV project research group. A risk-based approach to community illicit drug toxicosurveillance: Operationalisation of the Emerging Drugs Network of Australia - Victoria (EDNAV) project. (2023) *International Journal of Drug Policy*, 122, art. no. 104251. DOI: 10.1016/j.drugpo.2023.104251
120. **Hall, N.Y., Le, L.**, Abimanyi-Ochom, J., Mihalopoulos, C. Measuring the importance of different barriers to opioid agonist treatment using best-worst scaling in an Australian setting. (2023) *Health Policy*, 138, art. no. 104939. DOI: 10.1016/j.healthpol.2023.104939
121. Holford, T.A., **Reupert, A.E.**, Tchernegovski, P., Rhoades, H. Parental mental illness in the family courts: A scoping review. (2023) *Journal of Child and Family Studies*, 32 (12), 3892-3907. DOI: 10.1007/s10826-023-02708-8
122. Syrjanen, R., Greene, S.L., Weber, C., Smith, J.L., Hodgson, S.E., Abouchedid, R., **Gerostamoulos, D.**, Maplesden, J., Knott, J., Hollerer, H., Rotella, J.-A., Graudins, A., **Schumann, J.L.**, EDNAV project research group. Characteristics and time course of benzodiazepine-type new psychoactive substance detections in Australia: Results from the Emerging Drugs Network of Australia - Victoria project 2020-2022. (2023) *International Journal of Drug Policy*, 122, art. no. 104245. DOI: 10.1016/j.drugpo.2023.104245
123. **Ince, C.**, Fontenelle, L.F., **Carter, A., Albertella, L.**, Tiego, J., Chamberlain, S.R., Rotaru, K. Clarifying and extending our understanding of problematic pornography use through descriptions of the lived experience. (2023) *Scientific Reports*, 13 (1), art. no. 18193. DOI: 10.1038/s41598-023-45459-8

124. Piquet-Pessôa, M., de Oliveira, J., Ribeiro, A.P., **Albertella, L.**, Ferreira, G.M., de Menezes, G.B., Fontenelle, L.F. Habit-, reward- and fear-related motivations in alcohol use disorder: A one-year prospective study. (2023) *Journal of Psychiatric Research*, 168, 263-268. DOI: 10.1016/j.jpsychires.2023.10.026
125. Schwartz, O.S., Amminger, P., Baune, B.T., Bedi, G., Berk, M., **Cotton, S.M.**, Daglas-Georgiou, R., Glozier, N., Harrison, B., Hermens, D.F., Jennings, E., Lagopoulos, J., Loo, C., Mallawaarachchi, S., Martin, D., Phelan, B., Read, N., Rodgers, A., Schmaal, L., Somogyi, A.A., Thurston, L., Weller, A., Davey, C.G. The Study of Ketamine for Youth Depression (SKY-D): Study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder. (2023) *Trials*, 24 (1), art. no. 686. DOI: 10.1186/s13063-023-07631-3
126. Salomon, A., Bartlett, M., Chenery, M., Jauncey, M., **Roxburgh, A.** Outrage and algorithms: Shifting drug-related stigma in a digital world. (2023) *International Journal of Drug Policy*, 122, art. no. 104224. DOI: 10.1016/j.drugpo.2023.104224
127. Munari, S.C., Traeger, M.W., Menon, V., Latham, N.H., Manoharan, L., Luhmann, N., Baggaley, R., MacDonald, V., Verster, A., Siegfried, N., Conway, B., Klein, M., Bruneau, J., **Stoové, M.A.**, Hellard, M.E., **Doyle, J.S.** Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis. (2023) *Liver International*, 43 (12), 2625-2644. DOI: 10.1111/liv.15705
128. Walker, S., **Dietze, P.**, Higgs, P., Ward, B., Treloar, C., **Stoové, M.**, Rathnayake, K., **Doyle, J.**, Hellard, M., Maher, L. Socioeconomic consequences of the COVID-19 pandemic for people who use drugs. (2023) *Australian Journal of Social Issues*, 58 (4), 907-925. DOI: 10.1002/ajs4.289
129. **Xia, T.**, **Picco, L.**, Lalic, S., **Buchbinder, R.**, **Bell, J.**, **Andrew, N.E.**, **Lubman, D.I.**, Pearce, C., Nielsen, S. Determining the impact of opioid policy on substance use and mental health related harms: Protocol for a data linkage study. (2023) *JMIR Research Protocols*, 12, e51825. DOI: 10.2196/51825
130. **Manning, V.**, **Roxburgh, A.D.**, **Savic, M.** Piloting the integration of SMART Recovery into outpatient alcohol and other drug treatment programs. (2023) *Addiction Science and Clinical Practice*, 18 (1), art. no. 52. DOI: 10.1186/s13722-023-00406-w
131. Dixon, H., Scully, M., Niederdeppe, J., Brennan, E., **O'Brien, K.**, **Vandenberg, B.**, Pettigrew, S., Wakefield, M. Can counter-advertising dilute marketing effects of alcohol sponsorship of elite sport: A field experiment. (2023) *Addiction*, 118 (12), 2360-2373. DOI: 10.1111/add.16317
132. Abdelsalam, S., Livingston, M., Quinn, B., Agius, P.A., Ward, B., Jamieson, L., **Dietze, P.** Correlates of poor oral health related quality of life in a cohort of people who use methamphetamine in Australia. (2023) *BMC Oral Health*, 23 (1), art. no. 479. DOI: 10.1186/s12903-023-03201-w
133. Savaglio, M., **Yap, M.B.H.**, Smith, T., Vincent, A., Skouteris, H. "I literally had no support": Barriers and facilitators to supporting the psychosocial wellbeing of young people with mental illness in Tasmania, Australia. (2023) *Child and Adolescent Psychiatry and Mental Health*, 17 (1), art. no. 67. DOI: 10.1186/s13034-023-00621-y
134. Pham, T.T.L., **O'Brien, K.S.**, Liu, S., Gibson, K., **Berecki-Gisolf, J.** Repeat self-harm and mental health service use after self-harm in Culturally and Linguistically Diverse communities: Insights from a data linkage study in Victoria, Australia. (2023) *Australian and New Zealand Journal of Psychiatry*, 57 (12), 1547-1561. DOI: 10.1177/00048674231177237
135. Myles, D., **Bennett, D.**, **Carter, A.**, Yücel, M., **Albertella, L.**, de Lacy-Vawdon, C., **Livingstone, C.** "Losses disguised as wins" in electronic gambling machines contribute to win overestimation in a large online sample. (2023) *Addictive Behaviors Reports*, 18, art. no. 100500. DOI: 10.1016/j.abrep.2023.100500
136. Aung, P., Goutzamanis, S., Douglass, C., **Stoove, M.**, Hellard, M., **Dietze, P.**, Higgs, P. Exploring opportunities for hepatitis C treatment uptake among people who inject drugs in Australia: A qualitative study. (2023) *Journal of Substance Use*, 30(1), 30-35. DOI: 10.1080/14659891.2023.2238317
137. Lorenzetti, V., Gaillard, A., Beyer, E., Kowalczyk, M., Kamboj, S.K., **Manning, V.**, Gleeson, J. Do mindfulness-based interventions change brain function in people with substance dependence? A systematic review of the fMRI evidence. (2023) *BMC Psychiatry*, 23 (1), art. no. 407. DOI: 10.1186/s12888-023-04789-7
138. Kirby, J., **Naren, T.** Cannabinoid hyperemesis syndrome in pregnancy: Challenges and opportunities. (2023) *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 63 (6), 746-752. DOI: 10.1111/ajo.13714

139. Price, O., Sutherland, R., Man, N., Bruno, R., **Dietze, P.**, Salom, C., Akhurst, J., Peacock, A. Trends and psychosocial correlates of same day polysubstance use among people who inject drugs in Australia, 2012-2022. (2023) *International Journal of Drug Policy*. DOI: 10.1016/j.drugpo.2023.104150
140. Brien, R., Volpe, I., **Grigg, J.**, Lyons, T., Hughes, C., McKinnon, G., Tzanetis, S., Crawford, S., Eade, A., Lee, N., Barratt, M.J. Correction: Codesigning drug alerts for health and community workers for an emerging early warning system in Victoria, Australia (Harm Reduction Journal, (2023), 20, (1), 30, 10.1186/s12954-023-00761-6). (2023) *Harm Reduction Journal*, 20 (1), art. no. 57. DOI: 10.1186/s12954-023-00783-0
141. Volpe, I., Brien, R., **Grigg, J.**, Tzanetis, S., Crawford, S., Lyons, T., Lee, N., McKinnon, G., Hughes, C., Eade, A., Barratt, M.J. Correction: 'We don't live in a harm reduction world, we live in a prohibition world': Tensions arising in the design of drug alerts (Harm Reduction Journal, (2023), 20, 1, (3), 10.1186/s12954-022-00716-3). (2023) *Harm Reduction Journal*, 20 (1), art. no. 55. DOI: 10.1186/s12954-023-00784-z
142. Tan, E.J., Raut, T., **Le, L.K.-D.**, Hay, P., Ananthapavan, J., Lee, Y.Y., Mihalopoulos, C. The association between eating disorders and mental health: An umbrella review. (2023) *Journal of Eating Disorders*, 11 (1), art. no. 51. DOI: 10.1186/s40337-022-00725-4
143. **Peart, A.**, **Horn, F.**, **Grigg, J.**, **Manning, V.**, Campbell, R., **Lubman, D.** Online peer-led support program for affected family members of people living with addiction: A mixed methods study. (2023) *International Journal of Mental Health and Addiction*, 22, 3790-3804. DOI: 10.1007/s11469-023-01082-2
144. **Mende, P.**, Chaffey, E. Examining the mental health care needs and outcomes of young people transitioning from out-of-home care (OOHC) in Australia. (2023) *Institutionalised Children Explorations and Beyond*, 11(1). DOI: 10.1177/23493003231182474
145. de Lacy-Vawdon, C., **Vandenberg, B.**, **Livingstone, C.** Power and other commercial determinants of health: An empirical study of the Australian food, alcohol, and gambling industries. (2023) *International Journal of Health Policy and Management*, 12(1), 1-14. DOI: 10.34172/ijhpm.2023.7723
146. **Douglass, C.H.**, Win, T.M., Goutzamanis, S., Lim, M.S.C., Block, K., Onsando, G., Hellard, M., Higgs, P., **Livingstone, C.**, Horyniak, D. Stigma associated with alcohol and other drug use among people from migrant and ethnic minority groups: Results from a systematic review of qualitative studies. (2023) *Journal of Immigrant and Minority Health*, 25 (6), 1402-1425. DOI: 10.1007/s10903-023-01468-3
147. **Lubman, D.I.**, **Manning, V.**, **Arunogiri, S.**, Hall, K., **Reynolds, J.**, **Stragalinis, P.**, **Petukhova, R.**, Gerhard, R., Tyler, J., Bough, A., Harris, A., **Grigg, J.** A structured, telephone-delivered intervention to reduce methamphetamine use: Study protocol for a parallel-group randomised controlled trial. (2023) *Trials*, 24 (1), art. no. 235. DOI: 10.1186/s13063-023-07172-9
148. **Curtis, M.**, Wilkinson, A.L., **Dietze, P.**, Stewart, A.C., Kinner, S.A., Winter, R.J., Aitken, C., Walker, S.J., Cossar, R.D., Butler, T., **Stoové, M.** Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study. (2023) *Harm Reduction Journal*, 20 (1), art. no. 42. DOI: 10.1186/s12954-023-00773-2
149. Huang, P.-C., Latner, J.D., **O'Brien, K.S.**, Chang, Y.-L., Hung, C.-H., Chen, J.-S., Lee, K.-H., Lin, C.-Y. Associations between social media addiction, psychological distress, and food addiction among Taiwanese university students. (2023) *Journal of Eating Disorders*, 11 (1), art. no. 43. DOI: 10.1186/s40337-023-00769-0
150. **Langford, A.V.**, Schneider, C.R., Lin, C.-W.C., Bero, L., Collins, J.C., Suckling, B., Gnjidic, D. Patient-targeted interventions for opioid deprescribing: An overview of systematic reviews. (2023) *Basic and Clinical Pharmacology and Toxicology*, 133 (6), 623-639. DOI: 10.1111/bcpt.13844
151. Brien, R., Volpe, I., **Grigg, J.**, Lyons, T., Hughes, C., McKinnon, G., Tzanetis, S., Crawford, S., Eade, A., Lee, N., Barratt, M.J. Co-designing drug alerts for health and community workers for an emerging early warning system in Victoria, Australia. (2023) *Harm Reduction Journal*, 20 (1), art. no. 30. DOI: 10.1186/s12954-023-00761-6
152. **Picco, L.**, **Jung, M.**, **Cangadis-Douglass, H.**, **Lam, T.**, **Nielsen, S.** Identifying prescription-opioid-related risks using prescription drug monitoring programs' algorithms and clinical screening tools. (2023) *Pharmacy*, 11 (5), 164. DOI: 10.3390/pharmacy11050164

153. Scully, M., Dixon, H., Brennan, E., Niederdeppe, J., **O'Brien, K.**, Pettigrew, S., **Vandenberg, B.**, Wakefield, M. Can counter-advertising exposing alcohol sponsorship and harms influence sport spectators' support for alcohol policies? An experimental study. (2023) *BMC Public Health*, 23 (1), art. no. 396. DOI: 10.1186/s12889-023-15250-5
154. LaMontagne, A.D., Cox, L.L., Lockwood, C., Mackinnon, A., **Hall, N.**, Brimelow, R., **Le, L.K.-D.**, Mihalopoulos, C., King, T. Correction: Evaluation of a workplace suicide prevention program in the Australian manufacturing industry: Protocol for a cluster-randomised trial of MATES in manufacturing (*BMC Psychiatry*, 2022, 22, (1), 799, 10.1186/s12888-022-04464-3). (2023) *BMC Psychiatry*, 23 (1), art. no. 98. DOI: 10.1186/s12888-023-04590-6
155. Schroeder, S.E., Wilkinson, A.L., O'Keefe, D., Bourne, A., **Doyle, J.S.**, Hellard, M., **Dietze, P.**, Pedrana, A. Does sexuality matter? A cross-sectional study of drug use, social injecting, and access to injection-specific care among men who inject drugs in Melbourne, Australia. (2023) *Harm Reduction Journal*, 20 (1), art. no. 9. DOI: 10.1186/s12954-023-00737-6
156. Volpe, I., Brien, R., **Grigg, J.**, Tzanetis, S., Crawford, S., Lyons, T., Lee, N., McKinnon, G., Hughes, C., Eade, A., Barratt, M.J. 'We don't live in a harm reduction world, we live in a prohibition world': Tensions arising in the design of drug alerts. (2023) *Harm Reduction Journal*, 20 (1), art. no. 3. DOI: 10.1186/s12954-022-00716-3
157. Curtis, S.J., Colledge-Frisby, S., Stewardson, A.J., **Doyle, J.S.**, Higgs, P., Maher, L., Hickman, M., **Stoové, M.A.**, **Dietze, P.M.** Prevalence and incidence of emergency department presentations and hospital separations with injecting-related infections in a longitudinal cohort of people who inject drugs. (2023) *Epidemiology and Infection*, 151, art. no. e192. DOI: 10.1017/S0950268823001784
158. Lim, J.S., Buckley, N.A., Cairns, R., **Schumann, J.**, Schaffer, A.L., Chitty, K.M. Substances detected during coroner postmortem toxicology analyses in poisoning- and nonpoisoning-related suicides. (2023) *JAMA Psychiatry*, 80 (11), 1121-1130. DOI: 10.1001/jamapsychiatry.2023.2289
159. **Picco, L.**, **Xia, T.**, **Bell, J.S.**, Pearce, C., **Buchbinder, R.**, **Lubman, D.I.**, **Nielsen, S.** Changes in opioid agonist treatment initiation among people prescribed opioids for pain following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis. (2023) *Drug and Alcohol Review*, 42 (7), 1639-1646. DOI: 10.1111/dar.13754
160. Fomiatti, R., Pienaar, K., **Savic, M.**, Keane, H., Treloar, C. Improving understandings of trauma and alcohol and other drug-related problems: A social research agenda. (2023) *International Journal of Drug Policy*, 121, art. no. 104198. DOI: 10.1016/j.drugpo.2023.104198
161. Dali, G., Logge, W., Riordan, B., Conner, T.S., **Manning, V.**, Millan, E.Z., McNally, G.P., Haber, P.S., Morley, K.C. The role of impulsivity in the relationship between affect and alcohol consumption in young adults. (2023) *Alcohol: Clinical and Experimental Research*, 47 (11), 2161-2168. DOI: 10.1111/acer.15192
162. **Roxburgh, A.**, Livingston, M., **Dietze, P.**, **Nielsen, S.**, Cogger, S., Bartlett, M., Day, C., Latimer, J., Jauncey, M., **Clark, N.** The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia. (2023) *Public Health*, 224, 90-97. DOI: 10.1016/j.puhe.2023.08.019
163. Logge, W., Hurzeler, T., **Arunogiri, S.**, Towers, E., Baillie, A., Haber, P.S., Morley, K. Hypothalamic-pituitary-adrenocortical response in alcohol-dependent patients during baclofen treatment and association with clinical outcome: Preliminary results. (2023) *Alcohol*, 112, 25-29. DOI: 10.1016/j.alcohol.2023.05.001
164. Lau, G., Gabbe, B., Mitra, B., **Dietze, P.**, Reeder, S., Cameron, P., Read, D.J., Symons, E., **Beck, B.** Biases in the collection of blood alcohol data for adult major trauma patients in Victoria, Australia. (2023) *Emergency Medicine Journal*, 40 (11), 744-753. DOI: 10.1136/emered-2023-213186
165. Naznin, E., **George, J.**, Driezen, P., Palazzi, K., Wynne, O., Nargis, N., Fong, G.T., Bonevski, B. Trend over time on knowledge of the health effects of cigarette smoking and smokeless tobacco use in Bangladesh: Findings from the International Tobacco Control Policy Evaluation Bangladesh Surveys. (2023) *Drug and Alcohol Review*, 42 (7), 1838-1849. DOI: 10.1111/dar.13735

166. Bourke, E.M., Douglas, N., Wilson, C.L., Anderson, D., **Nehme, Z.**, Babl, F.E., Paediatric Research in Emergency Departments International Collaborative (PREDICT). Acute severe behavioral disturbance requiring parenteral sedation in pediatric mental health presentations to emergency medical services: A retrospective chart review. (2023) *Annals of Emergency Medicine*, 82 (5), 546-557. DOI: 10.1016/j.annemergmed.2023.04.028
167. Livingston, M., Room, R., Chikritzhs, T., Taylor, N., Yuen, W.S., **Dietze, P.** Trends in alcohol-related liver disease mortality in Australia: An age-period-cohort perspective. (2023) *Addiction*, 118 (11), 2156-2163. DOI: 10.1111/add.16275
168. **Sturgiss, E.**, Advocat, J., **Lam, T.**, **Nielsen, S.**, Ball, L., Gunatillaka, N., **Martin, C.**, **Barton, C.**, Wah Michael Tam, C., Skouteris, H., Mazza, D., **Russell, G.** Multifaceted intervention to increase the delivery of alcohol brief interventions in primary care: A mixed-methods process analysis. (2023) *British Journal of General Practice*, 73 (735), E778-E788. DOI: 10.3399/BJGP.2022.0613
169. Trytell, A., Osekowski, M., Zentner, D., **Nehme, Z.**, James, P., Pflaumer, A., Semsarian, C., Ingles, J., Stub, D., La Gerche, A., Paratz, E.D. Prevalence of illicit drug use in young patients with sudden cardiac death. (2023) *Heart Rhythm*, 20 (10), 1349-1355. DOI: 10.1016/j.hrthm.2023.06.004
170. McKetin, R., Clare, P.J., Castle, D., Turner, A., Kelly, P.J., **Lubman, D.I.**, **Arunogiri, S.**, **Manning, V.**, Berk, M. How does a family history of psychosis influence the risk of methamphetamine-related psychotic symptoms: Evidence from longitudinal panel data. (2023) *Addiction*, 118 (10), 1975-1983. DOI: 10.1111/add.16230
171. Gao, C.X., Filia, K.M., Bedi, G., Menssink, J.M., Brown, E., Rickwood, D.J., Parker, A.G., Hetrick, S.E., Herrman, H., Hickie, I., Telford, N., McGorry, P.D., **Cotton, S.M.** Understanding the complexity, patterns, and correlates of alcohol and other substance use among young people seeking help for mental ill-health. (2023) *Social Psychiatry and Psychiatric Epidemiology*, 58 (10), 1457-1467. DOI: 10.1007/s00127-023-02444-w
172. **McNeilage, A.G.**, **Nielsen, S.**, Murnion, B., Ashton-James, C. Experiences of misuse and symptoms of dependence among people who use gabapentinoids: A qualitative systematic review protocol. (2023) *BMJ Open*, 13 (9), art. no. e073770. DOI: 10.1136/bmjopen-2023-073770
173. Bradlow, R.C.J., Hicks, B., Mu, T., Pham, D., Sharkey, M., Plumley, N., **Lubman, D.I.**, **Arunogiri, S.** Management of opiate dependence related to dihydrocodeine-sorbitol misuse. (2023) *Medical Journal of Australia*, 219 (5), 200-201. DOI: 10.5694/mja2.52060
174. Kunstler, B.E., **Smith, L.**, Langmead, C.J., Goodwin, D.M., Wright, B., Hatty, M.A. "We don't want to run before we walk": The attitudes of Australian stakeholders towards using psychedelics for mental health conditions. (2023) *Public Health Research and Practice*, 33 (3), art. no. e3332321. DOI: 10.17061/phrp3332321
175. Colton, E., Wilson, K.-E., Chong, T.T.-J., **Verdejo-Garcia, A.** Dysfunctional decision-making in binge-eating disorder: A meta-analysis and systematic review. (2023) *Neuroscience and Biobehavioral Reviews*, 152, art. no. 105250. DOI: 10.1016/j.neubiorev.2023.105250
176. **Christensen, E.**, Brydevall, M., **Albertella, L.**, Samarawickrama, S.K., Yücel, M., **Lee, R.S.C.** Neurocognitive predictors of addiction-related outcomes: A systematic review of longitudinal studies. (2023) *Neuroscience and Biobehavioral Reviews*, 152, art. no. 105295. DOI: 10.1016/j.neubiorev.2023.105295
177. **Haines, S.**, **Savic, M.**, **Nielsen, S.**, **Carter, A.** Opioid-related policy changes: Experiences and perspectives from people who use opioids to manage non-cancer chronic pain. (2023) *Drug and Alcohol Review*, 42 (6), 1482-1492. DOI: 10.1111/dar.13683
178. Clay, S., Wilkinson, Z., Ginley, M., **Arunogiri, S.**, Christmass, M., Membrey, D., MacCartney, P., Sutherland, R., Colledge-Frisby, S., Marshall, A.D., Nagle, J., Degenhardt, L., Farrell, M., McKetin, R. Perspectives and sentiments on contingency management from people who use methamphetamine. (2023) *Drug and Alcohol Review*, 42 (6), 1427-1437. DOI: 10.1111/dar.13691
179. **Naren, T.**, MacCartney, P., Crawford, S., **Cook, J.** People who use drugs in hospital settings: 'Moving towards a person-centred harm reduction model'. (2023) *Drug and Alcohol Review*, 42 (6), 1529-1533. DOI: 10.1111/dar.13692
180. Leung, J., Mekonen, T., Wang, X., **Arunogiri, S.**, Degenhardt, L., McKetin, R. Methamphetamine exposure and depression—A systematic review and meta-analysis. (2023) *Drug and Alcohol Review*, 42 (6), 1438-1449. DOI: 10.1111/dar.13670

181. Laslett, A.-M., Room, R., Kuntsche, S., Anderson-Luxford, D., Willoughby, B., Doran, C., Jenkinson, R., Smit, K., **Egerton-Warburton, D.**, Jiang, H. Alcohol's harm to others in 2021: Who bears the burden? (2023) *Addiction*, 118 (9), 1726-1738. DOI: 10.1111/add.16205
182. Gray, S.E., **Di Donato, M.**, Sheehan, L.R., **Iles, R.**, **Collie, A.** The prevalence of mental health service use in Australian workers with accepted workers' compensation claims for low back pain: A retrospective cohort study. (2023) *Journal of Occupational Rehabilitation*, 33 (3), 602-609. DOI: 10.1007/s10926-023-10098-3
183. Hwang, C., Takano, T., So, R., Sahker, E., Kawakami, S., **Livingstone, C.**, Takiguchi, N., Ono-Kihara, M., Kihara, M., Furukawa, T.A. Prevalence of gambling disorder and its correlates among homeless men in Osaka city, Japan. (2023) *Journal of Gambling Studies*, 39 (3), 1059-1076. DOI: 10.1007/s10899-022-10121-x
184. Madawala, S., Enticott, J., **Sturgiss, E.**, **Selamoglu, M.**, **Barton, C.** The impact of smoking status on anticipated stigma and experience of care among smokers and ex-smokers with chronic illness in general practice. (2023) *Chronic Illness*, 19 (3), 557-570. DOI: 10.1177/17423953221101337
185. Hocking, J.S., Watson, C., Chondros, P., Sawyer, S.M., **Ride, J.**, Temple-Smith, M., Boyle, D., Skinner, R., Patton, G.C., Lim, M.S.C., Pirkis, J., Johnson, C., Newton, S., Wardley, A., Blashki, G., Guy, R., Dalziel, K., Sanci, L. Will a fee-for-service payment for a young people's health assessment in general practice increase the detection of health risk behaviours and health conditions? Protocol for a cluster randomised controlled trial (RAd Health Trial). (2023) *BMJ Open*, 13 (8), art. no. e074154. DOI: 10.1136/bmjopen-2023-074154
186. Faller, J., **Le, L.K.-D.**, Chatterton, M.L., Perez, J.K., Chiotelis, O., Tran, H.N.Q., Sultana, M., **Hall, N.**, Lee, Y.Y., Chapman, C., Newton, N., Slade, T., Sunderland, M., Teesson, M., Mihalopoulos, C. A systematic review of economic evaluations for opioid misuse, cannabis and illicit drug use prevention. (2023) *British Journal of Psychiatry Open*, 9 (5), art. no. e149. DOI: 10.1192/bjo.2023.515
187. Colledge-Frisby, S., Rathnayake, K., **Nielsen, S.**, **Stoove, M.**, Maher, L., Agius, P.A., Higgs, P., **Dietze, P.** Injection drug use frequency before and after take-home naloxone training. (2023) *JAMA Network Open*, 6 (8), p. E2327319. DOI: 10.1001/jamanetworkopen.2023.27319
188. Nguyen, E., Meadley, B., Harris, R., Rajaratnam, S.M.W., **Williams, B.**, **Smith, K.**, **Bowles, K.-A.**, Dobbie, M.L., Drummond, S.P.A., Wolkow, A.P. Sleep and mental health in recruit paramedics: A 6-month longitudinal study. (2023) *Sleep*, 46 (8), art. no. zsad050. DOI: 10.1093/sleep/zsad050
189. **Morgan, K.**, Solomon, L.M., Jones, N., **Picco, L.**, **Nielsen, S.** Building knowledge in opioid prescribing in post-operative treatment. (2023) *International Journal of Pharmacy Practice*, 31 (4), 403-408. DOI: 10.1093/ijpp/riad024
190. Strike, T., D'Angelo-Kemp, D., **Searby, A.** Exploring the effectiveness of a regional nurse practitioner led, long-acting injectable buprenorphine-based model of care for opioid use disorder. (2023) *International Journal of Mental Health Nursing*, 32 (4), 1129-1137. DOI: 10.1111/inm.13154
191. **Grigg, J.**, **Manning, V.**, **Cheetham, A.**, Greenwood, C.J., Youssef, G., Lockie, D., Bell, R., **Stragalinos, P.**, Bernard, C., **Lubman, D.I.** Risky alcohol consumption among women in Australia attending breast screening services: An exploratory cross-sectional study. (2023) *Addiction*, 118 (8), 1493-1506. DOI: 10.1111/add.16191
192. Rathnayake, K., Agius, P.A., Ward, B., Hickman, M., Maher, L., **Stoové, M.**, **Doyle, J.S.**, Hellard, M., Wilkinson, A., Quinn, B., Crawford, S., Sutton, K., **Dietze, P.** The impacts of COVID-19 measures on drug markets and drug use among a cohort of people who use methamphetamine in Victoria, Australia. (2023) *Addiction*, 118 (8), 1557-1568. DOI: 10.1111/add.16189
193. Larney, S., Jones, N.R., Hickman, M., **Nielsen, S.**, Ali, R., Degenhardt, L. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17. (2023) *Addiction*, 118 (8), 1527-1539. DOI: 10.1111/add.16178
194. Moller, C.I., Badcock, P.B., Hetrick, S.E., Rice, S., Berk, M., Witt, K., Chanen, A.M., Dean, O.M., Gao, C., **Cotton, S.M.**, Davey, C.G. Predictors of suicidal ideation severity among treatment-seeking young people with major depressive disorder: The role of state and trait anxiety. (2023) *Australian and New Zealand Journal of Psychiatry*, 57 (8), 1150-1162. DOI: 10.1177/00048674221144262

195. Bhad, R., Achab, S., Rafei, P., Kathiresan, P., Ardabili, H.M., Butner, J., Orsolini, L., Melby, K., Farokhnia, M., Narasimha, V.L., Ridley, K., Tolomeo, S., Kanabar, M., Matanje, B., Grandinetti, P., Potenza, M., Ekhtiari, H., Baldacchino, A., Chattopadhyay, A., Gianluca, B., Hung, C.-C., Jackson, D., Sallah, E., Hanafi, E., Gunnthorsdottir, E., Fonseca, F., Bhatia, G., Tzeferakos, G., Nutakor, H.S., Elkholy, H., Ullah, I., Long, J., Handuleh, J., Allagoa, L.E., Sadeghi, M., Vahidi, M., Aljenibi, M., Shalbafan, M., Bach, P., Huh, S.Y., Abdulkadir, S., Toyoshima, T., **Phan, V.**, Elsayy, W., ISAM NEXt Consortium. An online global survey and follow-up expert groups on the scope and needs related to training, research, and mentorship among early-career addiction medicine professionals. (2023) *Global Mental Health*, 10, art. no. e44. DOI: 10.1017/gmh.2023.35
196. **Langford, A.V.**, Lin, C.C.W., Bero, L., Blyth, F.M., Doctor, J., Holliday, S., Jeon, Y.-H., Moullin, J., Murnion, B., **Nielsen, S.**, Osman, R., Penm, J., Reeve, E., Reid, S., Wale, J., Schneider, C.R., Gnjidic, D. Clinical practice guideline for deprescribing opioid analgesics: Summary of recommendations. (2023) *Medical Journal of Australia*, 219 (2), 80-89. DOI: 10.5694/mja2.52002
197. Chitty, K.M., Buckley, N.A., Lim, J., Ali, Z., **Schumann, J.L.**, Cairns, R., Daniels, B., Pearson, S.A., Preen, D.B., Schaffer, A.L. Psychotropic and other medicine use at time of death by suicide: A population-level analysis of linked dispensing and forensic toxicology data. (2023) *Medical Journal of Australia*, 219 (2), 63-69. DOI: 10.5694/mja2.51985
198. Gunn, J., O'Keefe, D., Draper, B.L., Djordjevic, F., Ryan, K., Kerr, P., Elsum, I., Gold, J., Layton, C., Chan, K., **Dietze, P.**, Higgs, P., **Doyle, J.**, **Stoové, M.A.**, Hellard, M., Pedrana, A. The eliminate hepatitis C (EC) experience study: Baseline characteristics of a cohort of people who inject drugs in Melbourne, Australia. (2023) *BMJ Open*, 13 (7), art. no. e071665. DOI: 10.1136/bmjopen-2023-071665
199. Marshall, A.D., Schroeder, S.E., Lafferty, L., Drysdale, K., Baldry, E., **Stoové, M.**, Dietze, P., Higgs, P., Treloar, C. Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study. (2023) *Journal of Substance Use and Addiction Treatment*, 150, art. no. 209066. DOI: 10.1016/j.josat.2023.209066
200. Schroeder, S.E., Treloar, C., Bourne, A., **Stoové, M.**, **Doyle, J.**, Hellard, M., Pedrana, A. Pre-empting stigma and complicating trauma: Narratives of gay and bisexual men who inject drugs in Australia. (2023) *Qualitative Health Research*, 33 (8-9), 688-700. DOI: 10.1177/10497323231173788
201. Miller, P., Coomber, K., Lowen, T., Taylor, N., Livingston, M., Scott, D., Buykx, P., Mayshak, R., Curtis, A., **Baldwin, R.**, Smith, J.A., Clifford, S., Chikritzhs, T. The impact of minimum unit price on police-recorded alcohol-related assault rates in the Northern Territory, Australia. (2023) *Journal of Studies on Alcohol and Drugs*, 84 (4), 615-623. DOI: 10.15288/jsad.22-00128
202. **Dietze, P.** Police drug seizures cannot solve the problem of toxic drug supply in North America. (2023) *American Journal of Public Health*, 113 (7), 745-746. DOI: 10.2105/AJPH.2023.307328
203. **Nielsen, S.**, **Picco, L.**, **Russell, G.**, Pearce, C., **Andrew, N.E.**, **Lubman, D.I.**, **Bell, J.S.**, **Buchbinder, R.**, **Xia, T.** Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes. (2023) *International Journal of Drug Policy*, 117, art. no. 104053. DOI: 10.1016/j.drugpo.2023.104053
204. Callinan, S., MacLean, S., **Dietze, P.M.** Drinking at home: Restricting alcohol availability is a key mechanism to reduce harms. (2023) *Drug and Alcohol Review*, 42 (5), 983-985. DOI: 10.1111/dar.13679
205. Rossell, S.L., Meikle, S.E., **Williams, M.L.**, Castle, D.J. Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder? (2023) *Australian and New Zealand Journal of Psychiatry*, 57 (7), 935-936. DOI: 10.1177/00048674231172691
206. Smit, K., Dowling, R., Livingston, M., Room, R., Laslett, A.-M., Ferrier, A., **Livingstone, C.**, Borland, R., Jiang, H. Trends in alcohol expenditure in Australia from 1984 to 2015–2016: An exploratory study. (2023) *Drug and Alcohol Review*, 42 (5), 1235-1245. DOI: 10.1111/dar.13662

207. Price, O., Maher, L., **Dietze, P.M.**, Bruno, R., Crawford, S., Sutherland, R., Salom, C., Dore, G.J., Peacock, A. COVID-19 vaccine attitudes and facilitators among people in Australia who inject drugs. (2023) *Drug and Alcohol Review*, 42 (5), 1066-1077. DOI: 10.1111/dar.13621
208. **Livingstone, C.** The end of 'responsible gambling': Reinvigorating gambling studies. (2023). *Critical Gambling Studies*, 4 (2), 1-14. DOI: 10.29173/cgs164

FURTHER INFORMATION

Any enquiries or comments regarding this publication including requests regarding use or reproduction should be directed to the Monash Addiction Research Centre

Monash University

Peninsula Campus
Level 2, Building D
Moorooduc Hwy
Frankston, VIC 3199

Tel: +61 3 9904 4262

Email: marc.info@monash.edu

CRICOS provider: Monash University 00008C